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To assess current methods of prediction of adverse pregnancy outcomes, develop a 
prediction model and assess diet and life style in preventing preeclampsia.  
 
Methods 
Meta-analyses performed to assess the role of abnormal 1st trimester biomarker levels 
in predicting PE and the predictive accuracy of 2nd trimester UAD indices for stillbirth. 
A prospective observational study was performed to assess the efficacy of maternal 
characteristics, biomarkers, arteriography and UADs for predicting adverse pregnancy 
outcomes. Previously published 1st trimester PE prediction models were validated 
using data collected from the observational study.  A systematic review on the effect of 
diet and life style based metabolic risk modifying interventions on PE was performed. 
 
Results 
The review of biomarkers found that abnormal levels were particularIy associated with 
early onset PE. The stillbirth review demonstrated a three-four fold increased risk of still 
birth with abnormal UAD. 1045 women were included for analysis in the prospective 
observational study. Our models’ detection rate (false positive rate of 15%) was 72% 
for PE; 48% PIH; 30 % SGA <10th centile; 57% SGA <5th centile and 67% stillbirth.  
 
In the validation study the observed discrimination ability in the derivation studies 
ranged from 0.70 to 0.954. When validated against the study cohort, the AUC varied 
importantly, ranging from 0.504 to 0.833. Dietary interventions were shown to reduce 
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The high heterogeneity of studies in the systematic reviews makes it difficult to draw 
firm conclusions regarding the use of biomarkers or UADs in screening for pregnancy 
complications. Our prospective study showed a role for haemodynamics as part of 
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Chapter 1: Introduction 
 
PE affects around 5% of pregnancies and is a major cause of maternal and perinatal 
morbidity and mortality.(1) It is a multisystem disease characterised by blood pressure 
≥140/90mmHg and protein in the urine (0.3g/24h) after 20 weeks gestation.  The only 
definitive treatment for PE is delivery. An important part of management for the 
obstetrician is deciding the appropriate time for delivery based on risks of the 
complications of PE developing, such as HELLP (haemolysis, elevated liver enzymes, 
low platelets), eclampsia and placental abruption; versus the risks of preterm delivery 
to the baby.  
 
The last MBRRACE report (published December 2017) showed a maternal mortality 
rate of 0.13/100 0000 with 3 deaths from PE between 2013-2015.(2) The management 
of PE and its associated complications gives rise to large health care costs 
(approximately £9000/person).(3) Patients are often admitted in a tertiary care facility 
and may need care in an intensive care unit. The neonatal mortality and morbidity 
associated with the disease is high due to preterm delivery, growth restriction and 
stillbirth.  
 
Modern medicine is increasingly focusing on preventing disease. Prediction and 
prevention of complications in pregnancy is an important part of routine antenatal care 
enabling interventions and treatment to be allocated to those that need it and reducing 
costs and the potential burden of unnecessary tests and treatments to women whom 
don’t need it.  The National Collaborating centre for Women’s and Children’s Health 
has issued guidelines on routine prenatal care recommending that at the first visit a 
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woman’s level of risk for PE should be evaluated by a series of maternal characteristics 
for example age and weight, to identify those at high risk and allow intensive 
monitoring.(4) However this approach would falsely classify two thirds of women as 
being high risk and in need of intensive monitoring and prophylactic aspirin therapy, 
highlighting the need for a better screening test.(5)   
 
The placenta is crucial to the development of preeclampsia. (6) PE is associated with 
poor placentation and incomplete remodelling of the utero-placental spiral arteries. In 
normal pregnancy the maternal spiral arteries are converted from narrow muscular 
vessels to wide non-muscular channels independent of maternal vasomotor control.(7, 
8) In pregnancies complicated by PE, placental abruption and birth of SGA neonates, 
there is histological evidence of impaired trophoblastic invasion of the spiral arteries 
and the persistence of high impedance in the uterine vessels, resulting in reduced 
utero-placental blood flow and placental hypoxia. (9-11) 
 
A number of angiogenic factors have been implicated in the pathogenesis of 
preeclampsia. Persistent placental hypoxia induces the expression of angiotensin II 
type I receptor agonistic autoantibodies (AT1-AA) which stimulate the production of 
sFlt-1, sENG and endothelin-1.(6, 12) sFlt-1 and sENG are anti-angiogenic factors 
produced by the placenta which are shown to be increased in pregnancies affected by 
preeclampsia.(13, 14) Soluble sFlt-1 is a splice variant of VEGF receptor-1, which 
binds to circulating PlGF and VEGF inhibiting their actions and decreasing their 
concentrations in the uteroplacental and maternal circulation.(15, 16) These angiogenic 
factors play an essential role in vascular remodelling, consequently a fall in their levels 
leads to endothelial dysfunction and development of the clinical symptoms of the 
disease.(17-21)(22-24) The defective angiogenesis leads to the failure of 
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cytotrophoblasts to convert from an epithelial to an endothelial phenotype and invade 
maternal spiral arteries.(23) Zhou et al. demonstrated that exogenous sFlt-1 inhibits 
placental cytotrophoblast invasion in vitro. (23) Maynard et al. showed that exogenous 
sFlt-1 administered to pregnant rats induces hypertension, proteinuria and glomerular 
endotheliosis. VEGF also induces nitric oxide and vasodilatory prostacyclins in 
endothelial cells, suggesting a role in decreasing vascular tone and blood pressure. 
(22, 25, 26) 
 
Maternal blood levels of sFlt-1, PlGF and VEGF have been shown to correlate with the 
severity of preeclampsia, with increasing levels of sFlt-1 and decreasing levels of 
VEGF and PlGF, associated with more severe and early onset disease.(27) Khalil et al. 
showed that placental concentrations of sFlt-1, sEng and PlGF mirrored maternal 
serum changes, consistent with the view that the placenta is the main source of these 
factors in pregnancy.(28, 29) Abnormal levels of these markers can be measured prior 
to the onset of disease. Decreased levels of PlGF and VEGF have been shown from 
the end of the first trimester in women that go on to develop preeclampsia.(15) 
Increased levels of sFlt-1 are not seen until the second trimester.(12, 30, 31) The ratio 
of sFlt-1/PlGF increases from around 5 weeks prior to disease onset and has been 
proposed as a predictive tool for preeclampsia.(15, 22) The SaPPPhirE study 
demonstrated the ratio to have a pooled sensitivity of 80% and specificity of 92%, 
positive LR of 10.5 and negative LR of 0.22 in predicting preeclampsia in low and high 
risk women.(16) Currently NICE have recommended measuring the ratio to rule out 
preeclampsia in women presenting with suspected preeclampsia between 20-34+6 
weeks gestation.(32) Khalil et al. looked at longitudinal changes in maternal serum 
PlGF and sFlt-1 in women at increased risk of preeclampsia. They showed PlGF levels 
to be significantly lower from 11 and 13 weeks onwards in women who developed early 
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and late PE respectively. They also showed an increase in the sFlt-1/PlGF ratio from 
11 weeks gestation in the early PE group.(12) 
 
In normal pregnancy PlGF steadily increases during the 1st two trimesters and peaks at 
29-32 weeks and then declines. In PE PlGF concentrations start to decrease 9-11 
weeks before the onset of hypertension and proteinuria.(33) Ghosh et al looked at 
PlGF and UADs in the early 2nd trimester as a screening tool for PE and individually 
they were strong predictors for PE but in combination their association with PE was not 
significant.(33)  
 
Previous studies have examined the use of UADs, maternal characteristics and 
different biochemical markers either in combination or alone to improve the detection of 
pregnancies at high risk of complications from poor placentation.(5, 33-37) A 
systematic review assessing the use of 1st trimester UADs for predicting adverse 
pregnancy outcome showed high specificities for predicting PE and intrauterine growth 
restriction but low sensitivities.(38) Many potential biomarkers have been identified but 
findings have been relatively inconsistent between studies. Detection rates for 
combinations of multiple markers have varied between 38-100%.(39) There’s therefore 
a need for further studies to assess the predictive value of different markers and find 
the best combination. (27, 39) 
 
Evidence for an association of raised AFP with PE and other adverse pregnancy 
outcomes is conflicting.(35, 40) Costa et al. 2008 showed that 2nd trimester AFP levels 
were significantly higher in a population that went on to have an adverse pregnancy 
outcome. (40) Whereas Kang et al. 2008 did not see any significant difference.(35) 
Currently the majority of studies have focused on 2nd trimester UADs and AFP. We 
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have shown that raised maternal serum AFP in the 2nd trimester is associated with a 
significant increase in the risk of developing PE and that detection can be improved 
when combined with 2nd trimester UADs. (41, 42) However, interventions to reduce the 
incidence of PE have greatest benefit when they are commenced in the 1st trimester 
indicating the need for an effective method of 1st trimester screening.(43) 
 
Kisspeptin-54 (metastin) was first identified as a suppressor of tumour metastasis and 
has been described in abundance in the placenta. As levels rise dramatically from 8 
weeks gestation coinciding with the time of peak trophoblastic invasion it is thought to 
play a key role in implantation and development. A small study measured kisspeptin 
levels between 8-14 weeks of gestation and found that levels were lower in women that 
had SGA neonates.(44) A subsequent study measured kisspeptin levels at 16-20 
weeks gestation and looked at the association with SGA and PE and also found that 
kisspeptin levels were significantly lower indicating that kisspeptin levels are reduced in 
conditions associated with poor placentation. (45)  
 
Women who develop PE are at an increased risk of cardiovascular disease in later 
life.(46) Cardiovascular disease is associated with increased central systolic blood 
pressure and arterial stiffness.  In women with established PE there is an increase in 
central aortic systolic blood pressure, pulse wave velocity and augmentation index 
which are measures of arterial stiffness. This increased arterial stiffness has been 
detected as early as eleven weeks gestation and can be measured non-invasively by 
using an Arteriograph.(47) 
 
A screening test with adequate sensitivity and specificity that can be performed in the 
1st trimester would be the ideal, in order to allow intervention at an earlier stage when it 
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is likely to be more effective. Implementation of an adequately sensitive and specific 
screening test would also enable further investigation into more preventative strategies. 
The current main prophylactic treatment for PE is aspirin. Extensive randomised 
studies have shown prophylactic low dose aspirin to be associated with a ten percent 
reduction in PE however a systematic review performed by Bujold et al. has shown 
50% risk reduction if treatment if commenced before 16 weeks gestation. (43, 48) The 
recently published findings of the ASPRE trial showed the administration of low dose 
aspirin to women at high risk of preterm preeclampsia resulted in a lower incidence of 
the disease than placebo. (49) 
 
There has been a rise in the number of prognostic models being developed in 
obstetrics, particularly for PE, however few seem to have been widely implemented. A 
recent systematic review by Kleinrouweler et al. identified 69 prediction models for PE, 
only 5 of these had been externally validated and model performance was found to be 
lower when externally rather than internally validated.  They recommended that 
systematic reviews should be performed to identify and validate existing models to 
decide whether a new model should be developed or an existing model updated.  (50) 
 
Other adverse pregnancy outcomes such as stillbirth and intra-uterine growth 
restriction are also associated with poor placentation with 60% of stillbirths being linked 
to placental complications. (51) The stillbirth rate in the UK is currently 5.1 per 1000 
and whilst there has been a downward trend over the past ten years, the UK has one of 
the highest stillbirth rates in the developed world. (52)  There is a huge need to reduce 
this rate particularly focussing on those occurring closer to full term.  
The RCOG have published a guideline on the investigation and management of the 
SGA fetus recommending that women who have 3 or more minor risk factors have 
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uterine artery Dopplers performed between 20-24 weeks and serial growth scans if 
these are abnormal. In the guideline PAPP-A<0.415 is considered a major risk factor 
and it is recommended that these women have serial growth scans regardless of 
uterine artery Doppler results.(53) Benton et al. looked at maternal plasma PlGF levels 
and placental histology in women with suspected fetal growth restriction. They found 
low PlGF identified placental fetal growth restriction with a 98.2% sensitivity and 75.1% 
specificity. This is clinically relevant as many fetuses are small due to constitutional 
factors and are otherwise well and at low risk of complications and could be managed 
expectantly. Conversely, those that are small due to placental problems are at high risk 
of stillbirth and serious neonatal complications. The ability to discriminate between 
those that are constitutionally small and those in which there is underlying placental 
pathology would enable improved management, focusing on those that are at risk of 
adverse perinatal outcome and reducing the number of scans and unnecessary 
interventions for those that are constitutionally small. (54) 
 
There is currently no routine screening test or guidance for predicting pregnancies at 
risk of stillbirth. A systematic review of biomarker and ultrasonic tests noted that none 
of 16 single, or 5 combined tests, did well as predictors of stillbirth. However, stillbirth 
attributed to placental dysfunction was moderately to strongly associated with low first 
trimester PAPP-A and abnormal uterine artery Doppler velocimetry in the second 
trimester.(55) Akolekar et al. demonstrated that the addition of PlGF improves the 
performance of screening by maternal factors and other biomarkers. They also found 
that whilst PAPP-A on its own or with UAD and ductus venosus pulsatility is useful in 
predicting stillbirth, its contribution was not significant once PlGF was added to the 





Section 1.1 Aims of thesis 
 
My thesis aims to develop a screening test for the prediction of PE and other adverse 
pregnancy outcomes as a result of poor placentation; and to validate pre-existing PE 
models. It also aims to find further preventative therapies. It will address these through 
the following objectives: 
A. To determine the accuracy of biomarkers for the prediction of women at risk of 
PE and other adverse pregnancy outcomes. 
B. To determine the accuracy of UADs for the prediction of PE and other adverse 
pregnancy outcomes 
C. To evaluate the predictive value of maternal characteristics and arteriography 
for the prediction of PE and other adverse pregnancy outcomes 
D. To validate pre-existing PE models 
E. To perform systematic reviews assessing the effectiveness of biomarkers, 
UADs and diet and lifestyle interventions in the prediction and prevention of PE 
and other adverse pregnancy outcomes 
 
The specific research questions that I have attempted to answer in this thesis are 
given below and summarised in a structured format in table 1.1. 
 Can 1st trimester maternal AFP, placental growth factor, Pregnancy 
associated plasma protein-A, beta-hCG and UADs in combination with 
maternal characteristics and arteriography be used for the prediction of 
women at risk of PE and other adverse pregnancy outcomes? 
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 Can serial PlGF/AFP levels be used to predict pregnancies affected by 
PE and other adverse outcomes? 
 Can kisspeptin be used as a biomarker for prediction of PE and other 
adverse pregnancy outcomes? 
 Can my primary study data be used to validate pre-existing PE models? 
 How accurate are 1st trimester blood biochemical markers for predicting 
PE? 
 Can UADs predict stillbirth? 
 Can diet and life style based metabolic risk modifying interventions 
reduce the incidence of PE? 
 
Table 1.1: Structured Questions for each chapter of this thesis 
Chapter 
Number 




Objective A:  To determine the accuracy of biomarkers for the prediction of women at 







levels of AFP, 
PlGF, 
Kisspeptin 
Serial levels of 













Objective B: To determine the accuracy of UADs for the prediction of PE and other 




















Objective C: To evaluate the predictive value of maternal characteristics and 






















Objective D: To validate pre-existing PE models 
6 Pregnant 







PE Review of pre-
existing PE 
models  and 
validation of 
data with my 
primary study 
data 
Objective E: To perform systematic reviews assessing the effectiveness of biomarkers, 
UADs and diet and lifestyle interventions in the prediction and prevention of PE and 
other adverse pregnancy outcomes 
3 Pregnant 
women in the 
1st trimester 
Measurement 






women in the 






















































Systematic reviews were carried out with a prospective protocol in line with the current 
Cochrane recommendations. For reviews containing randomised controlled trials the 
PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) 
guidelines were adhered to and for those containing observational studies MOOSE 
(Meta-analysis of Observational Studies) guidelines were followed.(57, 58) 
 
Section 2.1 Systematic reviews of Effectiveness (Metabolic risk modifying 
agents, Biomarkers) 
 
Study Identification and Selection 
Questions were focused and well defined detailing population, intervention/test, 
comparison and study design. Major electronic databases were searched including 
MEDLINE, EMBASE and Cochrane. Hand searches of reference lists were also 
performed to identify any relevant articles that were not captured by the electronic 
searches. Language restrictions were not applied.  Study selection was performed in 
two stages. First the electronic searches were scrutinized and appropriate studies were 
identified by two reviewers. Copies of the full manuscripts of all citations that were likely 
to meet the selection criteria were obtained. The full text of these was assessed by 
both reviewers independently and studies that fulfilled the inclusion criteria were 




Study quality assessment and data extraction 
The quality of the selected primary randomized controlled trials was evaluated based 
on accepted contemporary standards.(59) The risk of bias of the individual studies was 
assessed in six domains including sequence generation, allocation concealment, 
blinding, incomplete outcome data, selective outcome reporting and other potential 
sources of bias.  The quality of observational studies; case-control and cohort, were 
assessed using the Newcastle-Ottawa scale.(60) Included studies were also assessed 
for consistency of results (heterogeneity). Individual studies were described by study 
type, intervention, numbers participating, population examined and study quality. Data 
was extracted in duplicate using pre-designed data extraction forms.  
 
Data synthesis 
Results were summarised as pooled relative risks (RR) or odds ratios (OR) with 95% 
confidence intervals. Heterogeneity was evaluated and if substantial heterogeneity was 
noted (I2>50%) possible causes were explored. To explore for sources of heterogeneity 
subgroup analyses were performed to see whether variations in clinical factors e.g. 
population, intervention or study quality affected the estimation of effect. We performed 
univariable meta-regression analyses followed by multivariable analysis to control for 
confounding among variables. Sensitivity analysis was also performed. Publication bias 
was explored for using Harbord’s or Eggers test. All analyses were carried out with 








Section 2.2 Systematic Reviews of Test Accuracy (Stillbirth and Doppler review) 
 
Systematic reviews of test accuracy were performed using established methodology in 
line with the recommendations of the Cochrane Collaboration including those of the 
Cochrane Methods Working Group on Screening and Diagnostic tests.  
 
Study Identification and Selection 
This was performed as detailed in section 1. 
 
Study quality assessment and data extraction 
Methodological quality of the selected primary studies was performed using Quality 
Assessment of Diagnostic Accuracy Studies criteria (QUADAS-2), which consists of 
four key domains: patient selection, index test, reference standard, flow and timing, 
which was adapted to the topic as necessary.(61) Each of these domains is assessed 
for risk of bias and concerns regarding applicability and classified as low or high risk or 
unclear. Data extraction was performed in duplicate by 2 reviewers on to pre-designed 
data extraction forms.  
 
Data Synthesis 
Sensitivities, specificities and LRs with their 95% confidence intervals for individual 
studies were derived.  A multilevel bivariate random effects model as implemented in 
the mentandi user-written command developed for Stata statistical software was used 
to obtain summary estimates of sensitivity and specificity. (62) From these, 
corresponding LRs and their 95% confidence intervals were also obtained.(63) This 
model also estimates the correlation between sensitivity and specificity as a random 
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parameter to represent the counterbalance between sensitivity and specificity due to 
threshold effect. 
 
Section 2.3 Primary Study 
 
This was a prospective observational study recruiting pregnant women attending the 
Royal London hospital in the 1st trimester of pregnancy. Written informed consent was 
obtained from those women agreeing to participate in the study and ethics approval 
was granted from the East of England ethics committee. 
 
Maternal history and characteristics 
Information was collected on age, ethnicity, method of conception, parity, smoking, 
alcohol and drug use, past medical and obstetric history, family history and drug 
history. Maternal weight and height were measured and body mass index calculated. 
 
Exclusion Criteria 
Women with multiple pregnancies or those affected by chromosomal or structural 
abnormalities, pregnancy loss under 24 weeks or gestational age more than 14 weeks 
were excluded.  
 
Arteriograph measurements 
Measurements were performed with women in the supine position. The parallel straight 
line distance between the suprasternal notch and symphysis pubis was measured 
(Jug-Sy) with a tape measure. This measurement provides an indirect measure of the 
aortic length. The arteriograph cuff was applied over the brachial artery for 
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measurement of aortic systolic blood pressure (SBPAO (mmHg)), pulse wave velocity 
(PWV (m/s)), augmentation index (AIx (%)) and mean arterial pressure (mmHg). The 
cuff records the early (direct) systolic wave (P1), late (reflected) systolic wave (P2) and 
diastolic waves (P3) secondary to central pressure changes. The Arteriograph first 
measures the systolic and diastolic blood pressure oscillometrically. The cuff is then 
deflated and re-inflated to measure the diastolic pressure and supra-systolic pressure 
(measured SBP plus 35mmHg). The pressure fluctuations in the brachial artery are 
detected by the cuff and the signals transmitted wirelessly to a laptop computer which 
contains software for analysis.  
  
The AIx% was calculated by dividing the pressure difference between the first forward 
wave due to systole and the second reflected wave (P2-P1) by the pulse pressure 
[AIx%=(P2-P1)x100/PP]. The aortic PWV (PWVAO) was calculated by dividing the 
distance between the suprasternal notch and the upper border of the symphysis pubis 
in metres by the time interval between the onset of the first systolic wave and the onset 
of the second reflected wave in seconds. Central SBP was estimated based on the 
relationship between the brachial and SBPAO in relation to the late systolic wave 
amplitude.  
 
All recordings were made by the same researcher. Results were not given to the 
women or their doctors and therefore did not influence subsequent care. 
 
UAD measurements 
Transabdominal ultrasound was used to measure the uterine artery flow velocity 
waveforms with colour pulsed Doppler using a Voluson E6 with a 3.5/5 MHz linear 
array. The high pass filter was set at 100Hz. With the power output kept within safety 
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guidelines. A sagittal section of the uterus was obtained and the cervical canal and 
internal cervical os identified. The transducer was then tilted from side to side and 
colour flow mapping used to identify each uterine artery along the side of the cervix and 
uterus at the level of the internal os. Pulsed Doppler was then applied with the 
sampling gate set at 2mm to cover the whole vessel and a reproducible uterine artery 
waveform was obtained, using an angle of insonation less than 30. Peak velocity of 
each waveform needed to be ≥60m/sec. UAD waveforms were obtained from both 
uterine arteries. In each artery the Pulsatility Index (PI), Resistance index, SD ratios 
and the presence or absence of a diastolic notch was recorded.  
 
All recordings were made by the same researcher. Results were not given to the 
women or their doctors and therefore did not influence subsequent care. 
 
Serum biomarkers 
Maternal serum was taken and stored for later analysis for the biomarkers AFP and 
PlGF. Immediate analysis for PAPP-A, β-hCG and kisspeptin were performed. 
 
Outcome measures 
The diagnosis of PE and gestational hypertension was made according to the 
International Society for the Study of Hypertension in Pregnancy criteria. Gestational 
hypertension is characterised by a systolic blood pressure ≥140mmHg and /or diastolic 
blood pressure ≥90mmHg on at least two occasions four hours apart developing after 
20 weeks gestation with no significant proteinuria. PE is characterised by gestational 
hypertension with proteinuria ≥300mg in 24hours or 30mg/mmol on urine protein 
creatinine ratio. Other outcomes examined were stillbirth, defined as fetal death after 
24 weeks gestation, placental abruption, gestational diabetes mellitus defined as a 
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fasting blood glucose level ≥5.6mmol/l or a 2 hour plasma glucose level≥7.8mmol/L 
and SGA less than the 5th or 10th centiles on customised growth charts.(64) 
 
Statistical Analysis 
Haemodynamic parameters and maternal serum biomarkers were converted into 
multiples of the median (MoM). Logistic regression with stepwise selection was 
performed to determine multivariate models in the prediction of PE, PIH, stillbirth, SGA 
<10th and 5th centile. Two final models were used to construct ROC curves and 
detection rates for specified false-positive rates, and areas under the curve (AUC) were 
calculated. 
 
Section 2.4 Validation Section 
 
Validation study population 
The validation study population was obtained as detailed in section 3. A further cohort 
of women obtained from previous similar research was added to this population in 
order to increase numbers for analysis and enable comparison of the models 
performance in the two groups. 
 
Prognostic models and study selection 
Medline was searched from inception until November 2016 without language 
restrictions. Models were selected for validation if they met the criteria detailed in table 
6.1. Models were excluded if they did not include 1 or more of the predictors and if they 




Quality assessment of prognostic models and data extraction 
The Quality in Prognosis studies (QUIPS) tool was used to assess the risk of bias in 
the included prognostic studies. The bias domains assessed were study participation, 
attrition, prognostic factor measurement, confounding measurement and account, 
outcome measurement and analysis and reporting. Each domain was assessed as 
either low, high or moderate risk of bias. (65) Individual studies were described by 
study design, variables measured, numbers participating and the number of PE events. 
 
Data synthesis 
Baseline characteristics of the validation cohort were described using median and 
interquartile ranges (IQR) and absolute and relative frequencies. Baseline clinical and 
demographic characteristics of the women recruited in the two cohorts used in the 
validation process were compared. We used Mann-Whitney U tests and Chi-squared 
tests or Fisher exact tests when needed for these comparisons. The comparison of 
both cohorts was further extended to evaluate the predictive performance of the 
models within the two groups of women included in the validation cohort. 
 
Validation of the models was performed by applying the regression coefficients that 
were published in the different derivation studies to our validation population. We 
obtained predicted probabilities of any PE for all models. 
 
Each models discrimination ability and its calibration were assessed using the area 
under the ROC curve. AUCs in the validation cohort were compared with the AUC 
reported by authors of the original models using a Z-test. (66) Evaluation of model 
calibration was performed by the Hosmer-Lemeshow goodness-of-fit test.  
 
All the analyses were carried out with Stata v13. 
40 
 
Chapter 3: Abnormal blood biomarkers in early pregnancy are associated with 




To evaluate the strength of association between abnormal levels of 1st trimester 
maternal blood biomarkers and the risk of PE.   
 
Methods 
Systematic review of literature that assessed the association between any abnormal 
maternal blood biomarker in the 1st trimester and PE with meta-analysis.  Results were 
summarized as pooled odds ratios with 95% confidence intervals.  
 
Results 
Thirty studies (65 538 women) were identified for inclusion. Twenty four studies 
assessed PE of any onset, 10 studied early onset PE and seven evaluated late onset 
PE (after 34 weeks of gestation). The biomarkers PAPP-A (OR 2.1, 95% CI 1.6, 2.6), 
PP13 (OR 4.4, 95% CI 2.9, 6.8), sFlt-1 (OR 1.3, 95% CI 2.9, 6.8), pentraxin (OR 5.3, 
95% CI 1.9, 15.0) and inhibin-A (OR 3.6, 95% CI 1.7, 7.6) were significantly associated 
with any PE. The odds of early onset PE were significantly increased when the 
biomarkers PlGF (OR 3.4, 95% CI 1.6, 7.2),   PAPP-A (OR 4.8, 95% CI 2.5, 22.5), 
PP13 (OR 7.5, 95% CI 2.5, 22.5), soluble endoglin (OR 18.5, 95% CI 8.4, 41.0) and 
inhibin-A (OR 4.1, 95% CI 1.9, 8.8) were abnormal. Two biomarkers, soluble endoglin 
(OR 2.1, 95% CI 1.9, 2.4) and inhibin-A (OR 1.9, 95% CI 1.4, 2.8) were significantly 





Abnormal levels of maternal blood biomarkers in the 1st trimester are significantly 
associated with PE, particularly early onset disease. 
 
Citation of paper arising from this work 
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The National Institute of Clinical Excellence (NICE) recommends routine early 
pregnancy assessment for risk of PE based on maternal history, and to offer low dose 
aspirin to those at high risk with early commencement of interventions having most 
benefit.(4, 48)  Previous studies have demonstrated low detection rates for PE with a 
screening strategy based on maternal history alone, highlighting the need for an 
effective 1st trimester screening test to allow early delivery of preventative therapies. 
(67, 68) 
 
Numerous studies have evaluated the role of various placental factors in the early 
prediction of PE. (69-94) Impaired placental perfusion is thought to lead to placental 
ischaemia and damage with the release of inflammatory factors contributing to clinical 
symptoms of the disease. (83-87) Although primary studies have evaluated the role of 
various biomarkers in early pregnancy, the overall strength of association between 
abnormal biomarkers in early pregnancy and PE is not clear. (95) In addition the 
relationship between maternal blood biomarkers and the timing of PE onset needs to 
be evaluated. 
                                             
 We undertook a systematic review and meta-analysis to evaluate the association 








Identification of studies 
We performed a systematic review with a prospective protocol in line with current 
recommendations. (59) We searched Cochrane, Embase and Medline databases from 
database inception up to April 2013 to identify relevant citations. Reference lists of all 
known primary and review articles were examined to identify cited articles that were not 
captured by the electronic searches. We contacted the authors of primary studies if 
relevant data were not reported.  Language restrictions were not applied. We used the 
following search term combination and their word variants: 1st trimester AND 
biomarker (PlGF, β-hCG, AFP, PAPP-A, nitric oxide, SVEGFR-1, sflt-1, inhibin-a, 
unconjugated oestriol, endoglin, activin-a, PP13, ADAM-12, dimethylarginine, 
pentraxin-3, P-selectin, adrenomedullin, visfatin, cell free DNA, cell free fetal DNA) 
AND preeclampsia.  
 
Study selection and data extraction 
The eligibility of studies was based on those that had assessed the association 
between any of the serum or plasma biomarkers in the 1st trimester and PE. 
Acceptable reference standards for PE were persistent high systolic (≥140mmHg) or 
diastolic (≥90mmHg) blood pressure and proteinuria (>0.3g/24 hours or a dipstick result 
of >1+, equivalent to 30mg/dl in a single urine sample or spot urine protein/creatinine 
ratio >30mg protein/mmol creatinine) of new onset after 20 weeks of gestation, 
according to the International Society for the Study of Hypertension in Pregnancy 
criteria. Included studies needed to describe the occurrence of PE conditional on the 
test result as means and standard deviations for continuous outcomes or in a manner 
that 2x2 classification tables could be constructed for dichotomous outcomes.(95) 
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Study selection was performed in two stages as detailed in our paper. (95) The 
electronic searches were examined and appropriate studies identified.  Two 
independent reviewers (RA and KC) reviewed the full text of identified papers, selected 
those that fulfilled the inclusion criteria and performed data extraction. Disagreements 
were resolved with input from a third reviewer (ST). If there were multiple publications 
of one dataset we only included the most recent or complete paper. 
 
Quality assessment of the included studies 
Selected studies methodological quality was assessed using the Newcastle-Ottawa 
scale.(60) For case control studies, we assessed the risk of bias in: the definition, 
selection and representativeness of the cases and controls; the comparability of the 
groups; and the ascertainment and completeness of exposure. For the cohort studies, 
we evaluated the risk of bias in: the selection and representativeness of the cohorts; 
their comparability; the exposure and outcome assessment; and the completeness of 
follow up. Studies were considered to have a low risk of bias if they scored 4 stars for 
selection, 2 for comparability or 3 stars for exposure or outcome. Studies that scored 0 
or 1 star for selection, 0 stars for comparability or 0 or 1 star for exposure or outcome 
were considered to have high risk of bias. Studies scoring between these were 
regarded to have medium risk of bias. (95) 
 
Data Synthesis 
Data synthesis was performed as documented in our previous paper. Results were 
summarised as odds ratios with 95% confidence intervals. When the marker 
concentration was provided as a continuous variable, we expressed the results as 
standardised mean differences with standard deviation. Results were pooled using an 
inverse variance weighted random effect approach. Both continuous and dichotomous 
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data were meta-analysed by converting odds ratios to effect size. This enabled the 
results to be summarised without loss of data and prevented data being misleading. 
(96) Publication bias was assessed by funnel plot analysis using Eggers test to 
evaluate for asymmetry. All analyses were performed with Revman 5.0 and Stata 12.1 




Characteristics of the included studies  
1,071 relevant citations were identified with full copies of 88 studies retrieved for further 
assessment. After full evaluation, 30 studies were included in the review (Fig 3.1, 
appendix 3.1). (30, 69-94, 97-99) of which seventeen (17/30, 57%) were case control 
studies and 13 (13/30, 43%) cohort studies. Sample sizes ranged from 45 to 47,922. 
The markers evaluated in these studies are detailed in figure 3.1.  
 
Fifty percent of the studies specified in detail the inclusion and exclusion criteria. Ten 
studies were on low risk women and eight included high risk women. The high risk 
studies included women with previous PE, pre-existing hypertension, diabetes or renal 
disease. Twelve studies didn’t detail the inclusion criteria. Women with multiple 
pregnancies and fetal anomalies were excluded.  The outcomes reported were early, 
late or any onset PE.   
 
Quality of the included studies 
Two thirds of the cohort studies (8/13, 62%) had a medium risk of selection bias, two 
thirds had high risk of comparability bias (8/13, 62%) and 90% (12/13) were medium 
risk for outcome assessment. Amongst case control studies, 12%, (2/17) had a high 
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risk of selection bias, 59% (10/17) were medium risk for comparability bias and almost 
half (41%) were low risk for exposure assessment (7/17). The quality assessment is 
provided in figure 3.2, and in Appendix 3.2.   
 













Search results combined from databases: 
Medline, Embase, Cochrane, (n =1070) 
Additional records identified 
through other sources  
(n =1) 





Inappropriate population (n=6) 
Inappropriate outcome (n=3) 
Inappropriate intervention (n=2) 
Inadequate study design (n=14) 
Data not analysable (n=31) 




Full-text articles assessed for eligibility 










































Association between early pregnancy biomarkers and PE 
Abnormal 1st trimester maternal biomarkers and PE of any onset were reported in 24 
studies which included 61,745 women. Abnormal levels of the biomarkers PAPP-A (9 
studies; OR 2.1, 95% CI 1.6, 2.6, I2 45%), PP13 (4 studies; OR 4.4, 95% CI 2.9, 6.8, I2 
50%), sFlt-1 (4 studies; OR 1.3, 95% CI 2.9, 6.8, I2 27%), pentraxin (1 study; OR 5.31, 
CI 1.9, 15.0) and inhibin-A (3 studies; OR 3.57, 95% CI 1.7, 7.6, I2 21%) were 
significantly associated with development of PE. There was no significant association 
for PlGF (4 studies; OR 1.94, 95% CI 0.81, 4.67, I2 83%), β-hCG (4 studies; OR 1.09, 
95% CI 0.86, 1.39, I2 0%) soluble endoglin (2 studies; OR 1.23, 95% CI 0.79, 1.94, I2 
0%) and VEGF (1 study; OR 2.44, 95% CI 0.99, 6) (see fig 3.3). 
 






Ten studies (15,760 women) evaluated six biomarkers with the development of PE 
before 34 weeks of gestation. PlGF (4 studies; OR 3.4, 95% CI 1.6, 7.2, I2 87%),   
PAPP-A (5 studies; OR 4.8, 95% CI 2.5, 22.5, I2 72%), PP13 (5 studies; OR 7.5, 95% 
CI 2.5, 22.5, I2 69%), soluble endoglin (2 studies; OR 18.5, 95% CI 8.4, 41.0, 14%) and 
inhibin-A (1 study; OR 4.1, 95% CI 1.9, 8.8) were significantly associated with early 
























The relationship of late onset PE and abnormal biomarker levels was evaluated in 
seven studies (12,053 women), examining five biomarkers. A significant association 
was seen for soluble endoglin (3 studies; OR 2.1, 95% CI 1.9, 2.4, I2 0%) and inhibin-A 
(2 studies; OR 1.9, 95% CI 1.4, 2.8, I2 0%). This association was not seen for abnormal 
levels of sFlt-1 (3 studies; OR 1.03, 95% CI 0.62, 1.74, I2 50%), PAPP-A (2 studies; OR 
1.44 95% CI 0.89, 2.32, I2 0%) and PlGF (3 studies; OR 1.85, 95% CI 0.7, 4.33, I2 89%) 























Assessment of publication bias 
Egger’s test for publication bias was significant for PAPP-A in association with any 
onset PE (p=0.04) and early onset PE (p=0.01). It was not significant for PlGF, sFlt-1 or 
PP13. Funnel plots demonstrating these results can be seen in appendix 3.3. We could 





This review shows that abnormal levels of maternal haematological biomarkers are 
associated with PE particularly early onset disease. Amongst the biomarkers, low 
PAPP-A and high levels of soluble endoglin were most predictive of early onset PE.  
 
Strengths and Limitations 
Our review is the first to provide summary estimates of the association between 
abnormal 1st trimester maternal blood biomarkers and onset of PE. Previous reviews 
have not quantified the strength of association for all relevant biomarkers limiting direct 
comparison of the markers. (39, 68, 100) and have only assessed four biomarkers from 
any trimester of pregnancy. (101) The approach of combining dichotomous and 
continuous data allowed direct comparison of biomarkers, improving the power of the 
analysis and avoiding any potential conflict that could arise from two separate analyses 
and ensuring heterogeneity was detected and not wrongly reported. (96) 
 
Our findings were limited by the amount of heterogeneity which may be due to studies 
reporting insufficient details of the population characteristics and underlying risk 
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factors. Many studies did not detail the gestation at onset of PE. Several studies 
identified could not be included as they reported results as medians with ranges or 
multiples of the median and despite efforts to contact the authors of relevant studies it 
was not possible to include all the existing evidence in this meta-analysis. 
 
Biomarkers and PE 
The underlying mechanism for the development of PE is thought to be impaired 
trophoblastic invasion of the maternal spiral arteries and their conversion from narrow 
muscular vessels to wide non-muscular channels independent of maternal vasomotor 
control. (7, 8) Impaired placental perfusion is thought to lead to placental ischemia and 
damage causing release of inflammatory factors which leads to platelet activation, 
endothelial dysfunction and consequently development of PE symptoms. (17, 19-21, 
99) Dysregulation and imbalance of sFlt-1, VEGF and PlGF; placental pro-angiogenic 
and anti-angiogenic vasoactive agents; have a significant role in the 
pathogenesis.(102)  
 
The pre-symptomatic levels of angiogenic biomarkers, appear to be linked to severity 
and timing of PE onset, especially for markers such as PlGF and PAPP-A, that are 
significantly associated with early onset, but not late onset disease.(27) For markers 
such as sFlt-1, there was a positive association with early onset PE, but not late onset. 
Some studies have suggested that PlGF levels are already significantly lower in the 1st 
trimester in women who develop PE but that changes in sFlt-1 occur later. (103) 
Evidence from studies measuring serial levels of angiogenic biomarkers have shown 
conflicting results which is likely to account for the high heterogeneity seen with our 
analysis.  Vatten et al. demonstrated lower levels of sFlt-1 in the 1st trimester in women 
developing preterm PE with levels substantially higher than controls in the 2nd 
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trimester. [38] Rana et al. demonstrated that 1st trimester levels of sFlt-1 were non-
significantly higher in women whom later developed PE but were significantly higher in 
the 2nd trimester. [27] The levels of some markers such as VEGF are known to be too 
low for detection in the 1st trimester. This could account for the paucity of studies on 
this marker, for which no association was demonstrated for PE.(39)   
 
Overall biomarkers were better for the prediction of early onset than late or any onset 
PE supporting the concept of two distinct disease entities with different 
pathophysiologies.(100)  Early onset PE being associated with inadequate placentation 
leading to an imbalance of pro- and anti-angiogenic factors with histology from 
placentae demonstrating abnormal villous and vascular morphology. Histology and 
morphology in late onset disease is not dissimilar to controls and disease is thought to 
be related to impaired glucose metabolism with a hyperdynamic low peripheral 
resistance maternal cardiovascular profile. In this situation it is unsurprising that there 
is a poor correlation between biomarker levels and late onset disease as trophoblastic 
invasion in the 1st trimester is likely to be normal. The mechanism of inadequate 
placentation being associated with early onset PE but not late onset, is supported by 
the sensitivity of UADs as a screening tool for early PE but not late onset disease.  
 
Implications for clinical practice and research 
Our review has identified which biomarkers are associated with the onset of PE, 
particularly early onset disease. The promising markers identified by this review, will 
allow the role of additional biomarkers to existing clinical prediction models to be 
assessed. Incorporating these biomarkers to current clinical prediction models will be 
the initial step in the promotion of individualised medicine practice allowing stratification 
of women early in their pregnancy, for targeted management. The only treatment that 
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has currently been found to have significant benefit in the prevention of PE is 
aspirin.(104)  
 
Any study on biomarkers should be standardised in its methodology enabling easier 
comparison and meta-analysis. The study population needs to be well defined, as well 
as the outcomes, with clear differentiation between late and early onset disease and its 
severity. This cohort of high risk women could subsequently be evaluated in future 























The aim of this review was to assess the predictive accuracy of UAD for stillbirth.  
 
Methods 
MEDLINE, EMBASE and Cochrane databases were searched without language 
restrictions from inception until March 2015. Studies that were included were those that 
assessed the association of abnormal UAD parameters and stillbirth. Two independent 
reviewers performed study selection, data extraction and quality assessment.  Study 
results were pooled and summary estimates of sensitivity, specificity, LRs and their 
95% confidence intervals were obtained. Diagnostic odds ratio was used to summarise 
overall test accuracy. 
 
Results 
340 relevant citations were returned form the literature searches with 34 considered in 
full. Thirteen 2nd trimester (85, 846 women, 508 stillbirths) studies met our search 
criteria, and two first (n=9935, 66 stillbirths) were included in the review. For 2nd 
trimester studies bivariate pooled estimate for sensitivity was 65% (95% CI 38 – 85%) 
and for specificity it was 82% (95% CI 72– 88%). The positive LR was 3.5 (95% CI 2.3 
– 5.5) and negative LR 0.43 (95% CI 0.22 – 0.85). The diagnostic odds ratio was 8.3 
(95% CI 3 – 22.4).  Pooled estimates for 1st trimester studies could not be obtained 




2nd trimester abnormal UAD indices are associated with a three to four fold increase in 
the risk of stillbirth. It is difficult to make any firm conclusions due to high heterogeneity. 
There is a role for individual patient data meta-analysis to define which Doppler 
parameter and threshold value should be measured. 
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Stillbirth is defined as a baby born without signs of live after 23+6 weeks of pregnancy. 
There has been a downward trend in the rate of stillbirths in the UK over the past 10 
years. The current rate is 5.1/1000. (52) 
 
The last CMACE report developed a new classification for conditions arising in 
pregnancy that caused or were associated with stillbirth. . This classification enabled a 
reduction in the number of stillbirths being reported as unexplained from 50% to 23%. 
They found the main causes or associated factors of stillbirth were antepartum or 
intrapartum haemorrhage (13%), intra-uterine growth restriction (IUGR – 10%) and 
specific placental conditions (9%). PE was associated with 4.7% of stillbirths. (52) 
These conditions are all associated with impaired placentation which can be measured 
indirectly by UADs demonstrating an increase in pulsatility index. Some studies have 
reported the association of elevated pulsatility/resistance index or notches with 
stillbirth. (5-7) The performance of UADs for prediction of stillbirth has varied across 
these studies and there’s also been variation in the reporting of outcomes and the 






The aims of this review are: 
 Assess the association between UADs and stillbirth and determine their 
predictive value 
 To compare the predictive value of UADs for stillbirth at different gestations and 




We undertook the systematic review with a prospective protocol in line with current 
recommendations.(59)  We searched MEDLINE, EMBASE and Cochrane databases 
from inception until March 2015 without language restrictions. Reference lists of 
primary and review articles were examined to capture those missed by electronic 
searches. No language restrictions were applied.  The authors of primary studies were 
contacted to obtain relevant data if it was not reported.  
 
We used the following combination of search terms: pregnan*, gravid*, “uterine artery 
dopplers”, Doppler, stillbirth, IUD, “intra-uterine death”.  Studies that evaluated the 
association of UAD with stillbirth were selected in a two stage process. Firstly the 
electronic searches were scrutinized and appropriate studies identified. Secondly, two 
independent reviewers reviewed the full text of identified papers and selected the 
studies that fulfilled the inclusion criteria.  Data was extracted in 2x2 tables for the 
incidence of stillbirth in women with abnormal UADs. We used the individual author’s 




All included studies methodological quality was assessed using the Quality 
Assessment of Diagnostic Accuracy Studies criteria (QUADAS-2), which consists of 
four key domains: patient selection, index test, reference standard, flow and timing.(61) 
Each of these domains is assessed for risk of bias and classified as low or high risk or 
unclear. 
 
Data for true positives, true negatives, false positives and false negatives was 
extracted from primary studies and used to estimate sensitivities, specificities and LRs 
with their 95% confidence intervals for individual studies.  Results for studies that were 
performed in the same trimester were pooled. A multilevel bivariate random effects 
model as implemented in the mentandi user-written command developed for Stata 
statistical software(62) was used to obtain summary estimates of sensitivity and 
specificity. From these indices corresponding LRs and their 95% confidence intervals 
were derived. (63) This model also estimates the correlation between sensitivity and 
specificity as a random parameter to represent the counterbalance between sensitivity 
and specificity due to threshold effect.  Due to the low number of studies included in the 
review we analysed the effect of covariates (screening general population versus high 
risk population) on diagnostic accuracy as measured by Diagnostic Odds Ratio using 
meta-regression weighted by the inverse of within study variance of log (DOR). Meta-




We found 340 relevant citations.  After screening titles and abstracts 34 were 
considered for further assessment. Full evaluation of these resulted in the identification 
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of 13 2nd trimester studies (n = 85,846) including 508 stillbirths and two 1st trimester 
studies (n=9935, 66 stillbirths) (Fig. 4.1, Table 4.1, appendix 4.2).  
 
Quality of the included studies 
The quality of the included studies is shown in table 4.2 and figures 4.2a and b. All of 
the 2nd trimester studies had a low risk of bias and concerns regarding applicability for 
flow and timing, reference standard (stillbirth) and index test (UAD assessment). Six of 
the 13 (46%) 2nd trimester studies had a high risk of bias and high concerns for 
applicability regarding patient selection. Both 1st trimester studies were assessed as 
low risk for these domains.  
 
 
Table 4.1. Characteristics of the included studies 
 














High SD ratio>2.6 
and bilateral 
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65 3  46 
Jamal et al. 
2013 
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Poon et al 
2013 
Low PI MoM 
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Proctor et al. 
2009 
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Axt-Fliedner 
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High Both RI 
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52 4 77 






>1.45 or  
1757 6 3.4 
Coleman et 
al. 2000 
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Search results combined from databases: 




Data not analysable (n=12) 
Inappropriate Outcome (n=2) 
Duplicated data (n=3) 
 
Studies included in the systematic review  
1st trimester studies (n=2) 




Full-text articles assessed for eligibility 
(n = 34) 




Figure 4.2a: Quality assessment of 1st trimester studies 
 
 





































































Madazali 2014 High Low Low Low High Low Low 
Jamal 2013 Low Low Low Low Low Low Low 
Poon  2013 Low Low Low Low Low Low Low 
Singh 2012 Low Low Low Low Low Low Low 
Iacovella 2012 Low Low Low Low Low Low Low 
Filippi  2011 High Low Low Low Low Low Low 
Proctor 2009 High Low Low Low High Low Low 
Fratelli 2008 Low Low Low Low Low Low Low 
Axt 
Fliedner 2005 High Low Low Low High Low Low 
Schwarz
e 2005 High Low Low Low High Low Low 
Coleman 2000 Low Low Low Low High Low Low 
Albiages 2000 Low Low Low Low Low Low Low 
Bewley 1991 Low Low Low Low Low Low Low 
Steel 1990 Low Low Low Low Low Low Low 
Fleischer 1986 High Low Low Low High Low Low 
 
Characteristics of the included studies 
Thirteen 2nd trimester studies were included.(106-118) Six studies were on high-risk 
women with co-morbidities such as hypertension, medical disorders, previous 
intrauterine growth restriction, placental abruption or stillbirth.(106-110, 118)  Seven 
were on an unselected group of women. Two studies were in women whom had  
abnormal biochemistry on Downs syndrome screening, including low PAPP-A and 
oestriol or high β-hCG/ AFP or Inhibin A. Doppler results were concealed from the 
clinicians in 4 of the studies(110, 111, 114, 117), open in 7 (110, 113) (106-108, 112, 
115)and they were not documented in two(116, 118). In 4 studies some of the women 
received aspirin or heparin (106, 108, 115, 118). Women on these medications were 
excluded in one study. (116) There was no documentation regarding the use of these 
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drugs in 8 of the studies. (107, 109-114, 117) The abnormal uterine artery parameters 
assessed varied between studies and included notching (unilateral/bilateral) (4 
studies), mean pulsatility index (PI) >1.45 (3 studies), mean PI >90th centile (2 studies), 
mean PI >95th percentile (1 study) mean resistance index (RI) >0.7 (1 study), mean RI 
>0.58 (2 studies), mean RI>95th centile (1 study) or systolic diastolic ratio >2.6 (2 
studies). Although different uterine artery parameters were used, the various UAD 
indices cut-offs are highly correlated. For example, PI of 1.45 corresponds to the 95th 
centile at 21-22 weeks, (119) mean RI of 0.73 and systolic to diastolic ratio of 4.05 at 
20 weeks corresponds to the 95th centile.(120) In general, all the cut-offs used 
represent Doppler indices at the upper extreme of the reference range.  
 
Two 1st trimester studies were included.(121, 122) One was on high risk women with a 
previous history of adverse pregnancy outcomes due to placental problems such as 
IUGR, PE, stillbirth or medical conditions including chronic hypertension, renal disease, 
thrombophilia.(122) In both studies clinicians were blinded to the Doppler results. There 
was no documentation regarding the use of anti-thrombotic or platelet agents in one of 
the studies and in one study they were not administered. In 1 study a mean RI >0.8 or 
bilateral notching was used as a cut off in the other study a cut off of mean RI >90th 
centile was used. 
 
Performance of 1st trimester UADs for predicting stillbirth 
The sensitivity of UADs in the 2 individual studies ranged from 14.5-100%. The 
specificity ranged from 64-91%. Due to the limited number of studies and participants 
and the high heterogeneity observed we could not obtain a pooled estimate of 




Performance of 2nd trimester UADs for predicting stillbirth 
We divided the studies into subgroups based on whether the study populations were 
unselected or at high risk of developing complications.  The sensitivity of UAD in the 13 
individual studies ranged from 25- 100%. The specificity ranged from 33-94%. Bivariate 
pooled estimate for sensitivity was 65% (95% CI 38 –85%) and for specificity, it was 
82% (95% CI 72– 88%). The positive LR was 3.5 (95% CI 2.3 –5.5) and negative LR 
0.43 (95% CI 0.22 – 0.85). Summary ROC curve and summary point are shown in Fig 
4.3. The prediction ellipse covers entirely the region of poor diagnostic performance 
(close to the diagonal of the ROC plane) denoting a high inter-study heterogeneity in 
both accuracy indices with smaller studies tending to give higher sensitivities but 
having almost no impact on pooled sensitivity given their small number of stillbirths. 
The diagnostic odds ratio provides an overall summary of test accuracy, which is 8.3 
(95% CI 3 – 22.4).  
 
Subgroup analysis of the high risk group (n=6) showed that the average sensitivity was 
90% (95% CI 36 – 99 %) with a pooled specificity of 69% (95% CI 54 – 81%). The 
positive LR was 2.9 (95% CI 1.8 – 4.9), negative LR 0.14 (95% CI 0.1 – 1.8) and 
diagnostic OR 21.3 (95% CI 1.2 – 380). The analysis demonstrated high heterogeneity 
which along with the small number of stillbirths makes it impossible to draw any 
conclusions about sensitivity of the test (Fig 4.4). The prediction ellipse and the 





















Figure 4.4: Subgroup analysis summary ROC curve for the performance of 2nd 
trimester UADs in predicting stillbirth in a high risk population 
 
In the seven 2nd trimester studies that performed UAD in an unselected population the 
prediction ellipse covers almost entirely the range of specificity being narrower for 
sensitivity (Fig 4.5). Pooled sensitivity is 46%, (95% CI: 32 – 60%), pooled specificity is 
88% (95% CI: 82 – 93%). The positive LR was 3.96 (95% CI: 3.1 – 5.0), negative LR 







Figure 4.5: Subgroup analysis summary ROC curve for the performance of 2nd 






The results of the meta-analysis have shown that abnormal 2nd trimester UAD indices 
in an unselected population increases the likelihood of stillbirth by a factor of three to 
four. Specificity was relatively high but sensitivity varied between studies. The high 
heterogeneity demonstrated could be caused by several factors defined a-priori, 
including the background risk of the populations recruited, differences in reported rates 
of stillbirth, different abnormal uterine artery parameters measured and different 
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chosen positivity thresholds. 
 
Strengths and limitations 
Included studies were of good quality reducing the risk of bias and the literature search 
was performed without language restrictions. Our study is limited by the heterogeneity. 
The populations tested varied between those that were high risk due to previous 
obstetric or medical history and those that were performed on the general pregnant 
population. There was a large amount of inter-study variation between the UAD 
parameters measured and their cut off values. We performed a subgroup analysis in 
order to control for these factors. 
 
Unfortunately we were unable to include some studies in our analysis due to difficulty 
obtaining primary data despite contacting the authors. Stillbirth has a variety of causes. 
Congenital structural abnormalities and infections are unlikely to have placental failure 
as an underlying cause and therefore no association with abnormal UAD. Therefore, 
the utility of UAD testing would be limited to those potentially avoidable stillbirths with 
placental failure as the underlying cause. A meta-analysis of UAD for the prediction of 
perinatal death was reported in 2000 which was based on four studies, perinatal death 
rather than stillbirth was reported. (123)  The positive and negative LRs in that study 
were 4.0 and 0.6, not too different to those found in our meta-analysis. 
 
Interpretation  
The stillbirth rate in the UK is 5.2 per 1000.  There has been a downward trend over the 
past ten years but it remains one of the highest stillbirth rates in the developed 
world.(52)  There is an urgent need to reduce this focussing on deaths occurring at or 
near term. There are no routine screening tests for detecting pregnancies at increased 
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risk of stillbirth. The policy of routine induction of labour from 41 weeks’ gestation was 
specifically introduced by the National Institute of Clinical Excellence (NICE) to prevent 
stillbirth, however it is yet to change the prevalence of term stillbirths.(124) Parity, racial 
origin, smoking, low educational level and previous adverse pregnancy outcome are all 
associated with stillbirth. The prevalence of these risk factors in the UK (nulliparity 
43%, smoking 19% and low education 49.6%) means that their combined prevalence is 
likely to result in the majority of the population being identified as screen positive. 
These risk factors have modest adjusted odds ratios between 1.6 and 2.9 for stillbirth 
with very low sensitivities. In contrast, risk factors with higher odds ratios such as 
abruption (adjusted odds ratio of 18.9) have low (1%) population prevalence. (125) 
 
Identification of a test with modest sensitivity, low false positive rate and a high positive 
LR has the potential to be useful for guiding intervention. This review has shown that 
UAD has these qualities if performed in the 2nd trimester.  UAD indices are relatively 
easy to measure and can be performed at the time of the 20 week anomaly scan. The 
additional cost is estimated to be £18-25 and an extra 5 minutes of time.(126) 
Pregnancies that are screen positive could then have closer surveillance by regular 
scans to check growth, liquor volume, umbilical and fetal Dopplers.  
 
Stillbirths occurring at the limits of viability are not preventable by elective delivery. 
Those occurring nearer term may well be preventable, since it is possible to deliver 
electively without increasing the risks of operative delivery.(127) Unfortunately, except 
the study of Poon et al, there was insufficient data provided in the other published 
individual studies to enable subgroup analysis based on timing of stillbirth.  An 
individual patient data meta-analysis would allow this to be assessed as well as 
determining which Doppler parameter and threshold value should be measured.  
Subsequent studies should assess whether intervention in screen positive women 
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could lead to a reduction in stillbirths, and if performance of UAD testing for stillbirth 


























Chapter 5: Prospective observational study to determine the accuracy of 1st 
trimester serum biomarkers and UADs in combination with maternal 
characteristics and arteriography for the prediction of women at risk of PE and 





Assess efficacy of biomarkers, arteriography and UADs for predicting hypertensive 
disease of pregnancy, SGA, placental abruption and stillbirth. 
 
Methods 
Prospective 1st trimester study. Transabdominal ultrasound was used to assess uterine 
artery blood flow. Arteriography was measured non-invasively and systolic blood 
pressure in the aorta (SBPAO), pulse wave velocity (PWV), augmentation index (Aix) 
and mean arterial pressure (MAP) were measured. Maternal serum was taken and 
levels of PlGF, AFP, PAPP-A and β-hCG determined. Haemodynamic parameters and 
maternal serum biomarkers were converted into multiples of the median (MoM). 
Logistic regression with stepwise selection performed to determine multivariate models. 
2 final models were used to construct ROC curves and detection rates for specified 
false-positive rates, and areas under the curve (AUC) were calculated. 
 
Results 
1045 women were left for analysis after exclusions (n=205, 16.4%). 14 (1.3%) 
developed PE, 23 (2.2%) PIH, 64 SGA <5th centile (6.1%), 118 SGA <10th centile 
(11.3%), 3 stillbirth (0.29%). Aix (p<0.027), SBPAO (p=0.002) and MAP (p=0.03) along 
with mean uterine artery PI (p=0.03), Afro-Caribbean ethnicity (p=0.013) and a history 
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of hypertension (p=0.047) were significantly associated with the development of PE. 
Detection rate was 72% for a FPR of 15%, AUC 0.81, 95% CI 0.69-0.93.  SBPAO 
(p=0.015), MAP (p=0.001) and maternal weight (p=0.001) were the only parameters 
significantly associated with PIH. Detection rate 48% for a 15% FPR, AUC 0.76, 95% 
CI 0.65-0.86. Low PAPP-A, PlGF and maternal hypertension were significantly 
associated with SGA <10th centile (p=0.007, 0.004 and 0.03 respectively), with a 
detection rate of 30% for a fixed FPR of 15%, AUC 0.608, 95% CI 0.54-0.68). For SGA 
<5th centile there was a significant association with low PlGF (p=0.00), PAPP-A 
(0.011), South Asian ethnicity (p=0.047) and maternal smoking (p=0.018). Detection 
rate 57% for a 15% fixed FPR, AUC 0.73, 95% CI 0.65-0.80). High AFP (p=0.041), low 
PlGF (p=0.036) and maternal smoking (p=0.025) were significantly associated with 
stillbirth with a detection rate of 67% for a 15% FPR. AUC 0.92, 95% CI 0.82-1.0).  
 
Conclusions 
In our population with a low prevalence of PE (1.3%) there was no demonstrable 
association between 1st trimester maternal serum biomarkers and hypertensive 
disease of pregnancy and between increased uterine artery PI and PIH. There was a 
significant association between low levels of PlGF and PAPP-A and SGA, and low 
levels of PlGF and AFP and IUD. The use of our model improved the prediction of 
preeclampsia from that based on current NICE guidelines. 
 
Citations of papers arising from this work 
Allen R, Bestwick J, Thangaratinam S, Aquilina J. Maternal blood biomarkers, 
arteriography and uterine artery Doppler (UAD) for the prediction of hypertensive 
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Assessment of pregnancies at risk of PE and intra-uterine growth restriction is made at 
the booking appointment based on clinical risk factors such as previous obstetric 
history and age.(4) However it is thought that this approach could falsely classify two 
thirds of women as being high risk exposing them to unnecessary interventions.(5)   
 
Currently a low pregnancy associated plasma protein-A (PAPP-A) ≤0.4 Multiples of the 
Median (MoMs) on 1st trimester screening is considered a major risk factor for having a 
SGA baby and it is therefore recommended that these women have serial scans from 
26-28 weeks gestation to assess fetal growth and placental blood flow. (53)  
 
Many maternal serum biomarkers have been investigated as potential screening tests 
for women at high risk of developing complications related to poor placentation such as 
PE, gestational hypertension and IUGR. A systematic review by Kuc et al. showed 
detection rates between 38-100% depending on combinations of multiple markers but 
concluded that prospective studies were needed to evaluate them in clinical practice. 
(39) 
 
Based on existing studies, our systematic review and our research on AFP in the 2nd 
trimester we decided to assess the role of AFP in the 1st trimester in combination with 
PlGF, UADs and arteriography as a predictive test for detecting pregnancies at high 
risk of developing PE and other adverse outcomes.(41, 42, 95)  We also assessed 
PAPP-A and β-hCG in those women whom had participated in the combined screening 




5.3 Materials and Methods 
 
This was a prospective observational study recruiting an unselected population of 
pregnant women attending the Royal London Hospital for dating or nuchal translucency 
scans in the 1st trimester of pregnancy (11-14 weeks gestation) between January 2013 
and July 2014. Written informed consent was obtained from those women agreeing to 
participate in the study. Ethics approval was granted by East of England Research 
Ethics Committee. Maternal characteristics and medical history were recorded. 
Arteriography, UAD measurements and maternal serum samples were taken.  
 
1st trimester serum kisspeptin levels were measured in a subset of women. Selection 
was random and dependent on availability of staff to process the samples and test kits. 
 
A further subset of women with mean UAD PI ≥1.96 were asked to return for serial 
monitoring of maternal serum PlGF and AFP at 20, 28 and 34-36 weeks gestation. A 
cut off of 1.96 for mean PI was used as per Costa’s paper as it was felt that these 
women were more likely to develop complications secondary to placental insufficiency. 
(40) 
 
Maternal history and characteristics 
Information was collected on age, ethnicity, method of conception, parity, smoking, 
alcohol and drug use, past medical and obstetric history, family history and drug 





These were performed as documented in chapter 2. 
 
UAD measurements 
These were performed as documented in chapter 2. 
 
Biomarker measurements 
Ten mls of maternal blood was taken in gold top gel tubes with no additives. The blood 
samples were allowed to clot and then centrifuged with removal of serum into aliquots 
which were stored at -80oC until analysed. 50µl samples were extracted for 
measurement of PlGF, 10 µl for AFP, 15 µl for PAPP-A and 10 µl for β-hCG. Elecsys 
test kits from Cobas were used and analysed by a Roche Cobas e601. The lower limit 
for detection of AFP was 0.5iu/ml, 3pg/ml for PlGF, 4mIU/L for PAPP-A and <0.1iu/L 
for β-hCG. Tests of repeatability were performed to determine between batch 
imprecision and revealed a coefficient of variation of 2.07% for AFP and 3.89% for 
PlGF. AFP and PlGF measurements were performed on an additional 1141 saved 
serum samples from a previous cohort of women who were recruited for similar 
research at our hospital.  
 
Kisspeptin samples were taken in a lithium heparin blood tube containing 200ul of 
aprotinin to inhibit plasma breakdown of peptides. Within a minute of taking the sample 
it was placed in a centrifuge, set to 4000rpm for 4 mins and spun at 4c. Immediately 
after this the plasma was separated into 3 eppendorf containers and frozen at -80c. 
Samples were analysed at Imperial College by Waljit Dhillo’s group using 
radioimmunoassay. There was never more than 1 minute left between each step as if 
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there’s a delay of more than 5min during a step there is a risk of kisspeptin breakdown 
or an interference effect, and results may be uninterpretable. 
 
Samples were analysed by an assessor blind to the clinical outcomes.  
 
Outcome measures 
As defined in chapter 2. Outcome data was obtained from the hospital maternity 
records, where data was missing the woman was contacted directly. 
 
Statistical Analysis 
Haemodynamic parameters, maternal serum biomarkers, UAD mean PI and MAP were 
converted into multiples of the median (MoM). PlGF, AFP, PAPP-A, β-hCG and MAP 
MoMs were adjusted for gestational age, weight and ethnicity. The biomarkers were 
also adjusted for smoking status. PAPP-A and β-hCG were in addition adjusted for IVF. 
Mean PI MoMs were adjusted by the crown-rump measurement and maternal height in 
meters. SBPAO, Aix75 and pulse wave velocity MoMs were adjusted for weight, parity 
and maternal age. Aix75 and SBPAO were also adjusted for ethnicity. Aix75 was further 
adjusted by maternal height.  
 
Univariate analysis was initially performed to determine variables with a significant 
association with our outcomes. Logistic regression with stepwise selection was then 
performed to determine multivariate models in the prediction of PE, PIH, stillbirth and 
SGA. Variables were included in the models based on a significant p value (p<0.05) on 
multivariate analysis only. Final models were used to construct ROC curves and 
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detection rates for specified false-positive rates, and areas under the curve (AUC) were 
calculated. 
 




Of the 1250 women recruited 1045 women were left for analysis after exclusions 
(n=205, 16.4%) (see figure 5.1 for explanation).   14 (1.3%) developed PE, 23 (2.2%) 
PIH, 64 SGA <5th centile (6.1%), 118 SGA <10th centile (11.3%) and 3 had a stillbirth 
(see figure 5.1).  There were no cases of placental abruption. The maternal 
characteristics of the various outcome groups are shown in table 5.1.   
 
5.4.1 PE 
Aix (p<0.027), SBPAO (p=0.002) and MAP (p=0.014) along with mean uterine artery PI 
(p=0.03), Afro-Caribbean ethnicity (p=0.013) and a history of hypertension (p=0.047) 
were significantly associated with the development of PE. There was no statistically 
significant association between levels of AFP (p =0.6) PlGF (p= 0.98) PAPP-A (p= 
0.52) and β-hCG (p=0.27). The detection rate for PE was 72% for a FPR of 15%, LR 
4.8, AUC 0.81, 95% CI 0.69-0.93. The detection rate using the current NICE 
recommendations, based on maternal characteristics, was 43% for FPR 11%, LR 3.9. 
 
PlGF and AFP data was also obtained for a cohort of 1141 women recruited 
prospectively for research in the 1st trimester of pregnancy (from 2010-2012) for 
prediction of PE and had serum saved. This gave us a total sample size of 2186 
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including 56 cases of PE. Demographic data for this population and comparison to my 
population are shown in chapter 6, table 6.3. This additional analysis was performed to 
see if results correlated with those above given the small number of preeclamptics in 
the initial sample. Univariately, PlGF MoM was then found to be significantly associated 
with PE (OR=0.16, 95% CI 0.04-0.72, p=0.016) but wasn’t significant in the multivariate 
model.  The findings for AFP remained unchanged. 
 

















1250 women recruited 
Women excluded 
(n=205) 
 47 no haemodynamics 
 4 no UAD 
 8 miscarriages 
 6 TOPs 
 2 Fetal anomalies 
 106 Outcome data not available 
 32 Blood results not available 
1045 remaining after exclusions 
 
Outcomes  
 PET (n=14) 
 PIH (n=23) 
 SGA <5th centile (n= 64) 
 SGA <10th centile (n= 118) 






SBPAO (p=0.015), MAP (p=0.001) and maternal weight (p=0.001) were the only 
parameters significantly associated with PIH. Detection rate for PIH was 48% for a 15% 
FPR, AUC 0.76, 95% CI 0.65-0.86. For PIH the strongest marker was PlGF (p = 0.07) 
compared to AFP (p= 0.83), PAPP-A (p= 0.54) and βhCG (p value=0.39) but none 
achieved statistically significant correlations. 
 
5.4.3 SGA 
Low PAPP-A and PlGF were significantly associated with SGA <10th centile (p=0.007 
and 0.004 respectively) but not AFP (p=0.754), βhCG (p=0.779) and mean PI 
(p=0.135). None of the haemodynamic parameters showed a statistically significant 
association with SGA <10th centile. A history of maternal hypertension was also a 
significant factor in the development of an SGA baby <10th centile (p=0.03). On 
multivariate analysis the detection rate was 30% for a fixed FPR of 15%, AUC 0.608, 
95% CI 0.54-0.68). 
 
For SGA <5th centile there was a significant association with low PlGF and PAPP-A 
(p=0.00 and 0.011 respectively) South Asian ethnicity (p=0.047) and maternal smoking 








Table 5.1: Maternal characteristics of control and outcome groups 
Maternal characteristic 
Control 




centile (n=118) IUD (n=3) 
Maternal age (years, 
median (range)) 30 (15-45) 31.5 (24-39) 34 (24-48) 30 (18-41) 31 (18-41) 35 (20-37) 
Weight(kg, median (range)) 61.5 (37-135) 61.5 ( 45-106) 69 (44-104) 61 (47-135) 62.5 (35-135) 73 (58-77) 
BMI 23 (15-51) 23 (19-41) 25 (17-36) 24 (18-45) 24 (16-45) 26 (24-26) 
Ethnicity 
Caucasian 342 5 8 17 37 1 
Afro-Caribbean 83 6 5 9 15 0 
South Asian 304 3 6 28 46 2 
Oriental 89 0 3 5 13 0 
Mixed/other 37 0 1 5 7 0 
Parity 
Nulliparous 482 8 17 30 59 1 
Parous-no previous PE 365 3 6 31 53 2 
Parous-Previous PE 8 3 0 3 6 0 
Family history of PE 
(mother/sister) 24 1 1 2 5 0 
Smoker 27 1 1 5 5 1 
Alcohol 11 0 0 1 3 0 
Recreational Drugs 2 0 0 0 0 1 
Conception 
Spontaneous 17 13 23 62 116 3 




None 679 12 20 50 93 3 
Essential hypertension 5 1 1 3 4 0 
Lupus /Antiphospholipid 
syndrome 4 0 0 0 0 0 
Renal disease 0 1 0 0 2 0 
Diabetes Mellitus 9 0 0 1 2 0 
Asthma 24 0 2 5 8 0 
Hyperthyroidism 2 0 0 1 2 0 
Hypothyroidism 19 0 0 4 5 0 
Sickle cell disease 0 0 0 0 0 0 
Medication during pregnancy 
None 716 12 19 53 95 2 
Aspirin 19 1 2 2 7 1 
Anti-thrombotics 4 0 0 0 1 0 
Anti-hypertensives 4 0 0 2 2 0 
AEDs 2 0 0 0 0 0 
Thyroxine 23 0 0 3 4 0 
Beta-mimetics 11 0 2 3 5 0 
Immunosupressants 4 1 0 0 1 0 
Insulin 5 0 0 1 0 0 
steroids 1 0 0 0 3 0 




High AFP (p=0.041) and low PlGF (p=0.036) were significantly associated with 
stillbirth, as was a maternal history of smoking (p=0.025) with a detection rate of 67% 
for a 15% FPR. AUC 0.92, 95% CI 0.82-1.0. No association was seen with 
haemodynamic parameters, increased uterine artery PI (p=0.59) or PAPP-A (p=0.44) 
and β-hCG (p=0.21). 
 
See table 5.2 for comparison of median MoMs in affected and unaffected pregnancies. 
See appendix 5.1 for full details of the logistic regression models, the univariate and 
multivariate odds ratios for prediction of each outcome and ROC curves. Appendix 5.2 















Table 5.2: Comparison of median MoMs in affected and unaffected pregnancies 
    PE PIH IUD SGA5 SGA10 
AIX50 Affected 1.09 1.03 0.96 1.03 1.00 
 
Unaffected 1.00 1.00 1.00 1.00 1.00 
 
p-value 0.027 0.104 0.364 0.201 0.555 
PWV Affected 1.03 1.05 1.16 1.00 1.01 
 
Unaffected 1.00 1.00 1.00 1.00 1.00 
 
p-value 0.848 0.133 0.439 0.786 0.603 
SBPAO Affected 1.11 1.05 1.00 1.01 1.00 
 
Unaffected 1.00 1.00 1.00 1.00 1.00 
 
p-value 0.002 0.015 0.635 0.331 0.858 
MAP Affected 1.08 1.09 1.03 0.99 0.99 
 
Unaffected 1.00 1.00 1.00 1.00 1.00 
 
p-value 0.014 0.001 0.390 0.625 0.335 
Mean 
UAD PI Affected 1.08 1.00 1.14 1.06 1.04 
 
Unaffected 1.00 1.00 1.00 1.00 1.00 
 
p-value 0.030 0.889 0.593 0.087 0.135 
AFP Affected 0.92 1.05 1.83 1.10 1.03 
 
Unaffected 1.00 1.00 1.00 0.99 1.00 
 
p-value 0.601 0.836 0.041 0.075 0.754 
Free β-
hCG Affected 0.83 0.91 0.65 1.05 0.90 
 
Unaffected 0.96 0.96 0.96 0.96 0.96 
 
p-value 0.266 0.399 0.206 0.522 0.779 
PAPPA Affected 0.76 0.93 1.24 0.87 0.90 
 
Unaffected 1.02 1.02 1.02 1.02 1.03 
 
p-value 0.524 0.542 0.438 0.011 0.007 
PlGF Affected 0.98 0.79 0.66 0.79 0.89 
Unaffected 1.00 1.00 1.00 1.01 1.01 
  p-value 0.981 0.071 0.036 0.000 0.004 
No corrections were made for multiple testing 
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5.4.5 Kisspeptin results 
Sixty two primiparous women had serum kisspeptin levels measured in the 1st 
trimester. Of these only one developed PE, 2 PIH, one SGA<5th centile, 2 SGA <10th 
centile and 5 GDM. No significant association between kisspeptin and any of the 
outcomes were found. Table 5.3 summarises the odds ratios and p-values.  
Table 5.3: Kisspeptin results 
Outcome OR 95% CI p-Value 
PE 0.87 (0.68-1.12) 0.291 
PIH 0.99 (0.85-1.16) 0.947 
IUD - - - 
SGA <5th centile 0.88 (0.68-1.13) 0.3 
SGA<10th centile 0.85 (0.69-1.03) 0.092 
 
5.4.6 Serial PlGF and AFP  
Serial results were obtained for 73 women. In this cohort of women there were 3 cases 
of PE, 4 PIH, 12 SGA<5th centile and18 SGA<10th centile. There was a significant 
association between low serial PlGF levels and SGA<5th (p=0.037) and 10th centiles 
(p=0.014). There was no significant association with any of the other outcomes. Serial 




This was a prospective cohort study with complete outcome data for 1045 unselected 
women who attended for their 1st trimester scan at the Royal London Hospital over an 
18 month time frame. All haemodynamic and UAD measurements were performed by 
the same assessor and biomarker levels were measured independently by assessors 
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who were blinded to the other variable results and outcome data. The population 
attending the Royal London is ethnically diverse with a large number of South Asian 
women. We managed to capture a large cross sample of our population which is 
demonstrated in table 5; our findings should therefore be widely applicable.  
 
In our study population there was a low incidence of PE (1.3%) and PIH (2.2%). We 
found that our model, combining maternal characteristics with biochemical, biophysical 
parameters and haemodynamics improved the detection of women at risk of 
developing preeclampsia to that of the current NICE recommendations based on 
maternal characteristics alone. In contrast to some other studies we didn’t find any 
association between abnormal levels of the 1st trimester biomarkers and PE/PIH. (30, 
69, 73, 76-79, 85-87, 94, 99, 128) There was a significant association between low 
levels of PlGF (p=0.036) and high levels of AFP (p=0.041) and IUD, and low levels of 
PlGF (p=0.004) and PAPP-A (p=0.007) and SGA <10th centiles and SGA <5th centile 
(p=0.011 and p=0.00 for PlGF and PAPP-A respectively). 
 
AFP is an oncofetal glycoprotein produced from the second month of pregnancy, 
initially by the yolk sac and from the third month by the fetal liver and gastrointestinal 
tract. It has been used as a screening test for open neural tube and abdominal wall 
defects. Maternal serum AFP rises from weeks 10 to 32 and then declines. Fetal to 
maternal transfer of AFP is thought to be via two routes, transplacental and 
transmembranous.  Unexplained mid trimester MSAFP elevations have been 
associated with an increased risk of SGA, preterm delivery, placental abruption and 
PE.(129-131) In the first and 2nd trimester evaluation of risk (FASTER) study involving 
33 000 women, MSAFP >2MoM was associated with placental abnormalities as well as 
IUGR (OR 2.7), miscarriage (OR 4.4) and intrauterine fetal death (OR 5.8) (129). 
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Walters et al. reported that 13% of women with elevated MSAFP developed PE 
compared to 1% of the women with normal MSAFP.(130) Williams et al (1992) 
compared 201 women with unexplained elevated MSAFP (greater than and including 
2.0 MoM) with 211 women with normal MSAFP.  A significant association was found 
between elevated MSAFP and PE, adjusted risk ratio (ARR) being 3.8.(131)  The 
association between AFP and adverse pregnancy outcome has been attributed to a 
breakdown in the placental barrier resulting in an increase in the diffusion of alpha-
fetoprotein from fetal to maternal serum. This is supported by the finding that fetal 
maternal haemorrhage of <0.1ml can cause a substantial elevation in MSAFP. (132) In 
a small morphometric study of placentae associated with raised MSAFP, a normal 
concentration of amniotic fluid AFP, and a normally formed fetus, the mean total 
placental volume, volume of parenchyma and villous surface area were increased, 
there were more areas of infarction and a lower fetal-placental weight ratio compared 
with the control group. (133) Boyd et al. propose that the reason 2nd trimester AFP may 
be raised in combination with a normally formed fetus can be attributed mainly to 
changes in the placenta which has the property of responding to an adverse 
environment by increasing its surface of exchange. 
 
From previous studies, including our own which demonstrated AFP as a promising 2nd 
trimester marker, we were disappointed that this study did not show it to have a role in 
1st trimester screening for hypertensive disease. (41, 42) At the commencement of this 
research there were no other publications that we could find assessing the association 
of 1st trimester AFP levels and PE. However during this research a paper was 
published in 2016 which demonstrated an association between raised AFP levels in the 
1st and 2nd trimester and PE, with values being inversely related to gestational age at 
delivery. They concluded that measurement of serum AFP at 11-13 and 19-24 weeks 
improved the prediction of preterm PE provided by maternal factors alone. They did 
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identify that its performance as a screening test was superior at 19-24 weeks than in 
the 1st trimester and that measurement alone in the 1st trimester is unlikely to improve 
the performance of screening provided by a combination of maternal factors, uterine 
artery PI, MAP and PlGF.(134) We hypothesise that our finding of no significant 
association between increased MSAFP and PE may be because endothelial damage in 
the 1st trimester is still not established. However we did show a significant association 
between increased 1st trimester AFP and IUD. This would be an interesting area for 
future research.  
 
PlGF is a member of the vascular endothelial growth factor subfamily and is expressed 
by trophoblast cells. It is a pro-angiogenic protein involved in the regulation of placental 
vascular development and maternal endothelial function during pregnancy. Changes in 
levels of PlGF or its inhibitory receptor have been implicated in the development of 
PE.(15, 22, 24, 135) We demonstrated an association between low PlGF and SGA. 
Previous research supports this finding.(85, 136) Our research does not support 
previous researcher’s evidence for demonstrating serial low levels of PlGF for 
predicting pregnancies at risk of PE. (91, 137) However there were only 3 
preeclamptics in the sample who had serial levels measured. Previous studies were 
retrospective case control so were able to select a large number of preeclamptics for 
measurement of PlGF levels. They also found that the levels were lower in those with 
preterm rather than term PE.  Our systematic review showed abnormal levels of PlGF 
to be significantly associated with early but not late or any onset PE.(95) It is likely that 
our study didn’t demonstrate an association between both one off 1st trimester or serial 
levels of PlGF because the numbers of early onset PE were so low leading us to 




We found an association between low PlGF and stillbirth supporting findings by 
Akolekar et al. In our three cases of stillbirth two weighed less than the 10th centile on 
customised growth charts. Placental histology was abnormal in two cases. In one case 
the placenta weighed less than the 3rd centile for gestational age with delayed 
maturation and chronic decidiutis; this patient also had PIH. The other was from the 
normally grown fetus which also showed delayed maturation. These findings suggest 
that at least two thirds of the cases of stillbirth were placentally mediated and supports 
the use of placental biomarkers such as PlGF for the prediction of stillbirth. 
 
PAPP-A is a syncitiotrophoblast derived insulin like growth factor binding protein 
protease that increases the bioavailability of insulin like growth factor. IGF is believed 
to play a role in fetal growth by mediating trophoblast invasion to the decidua and 
regulating steroidogenesis and glucose and amino acid transport in the chorionic villi. It 
is therefore not surprising that a low PAPP-A is associated with a higher incidence of 
PE and other adverse pregnancy outcomes secondary to poor placentation such as 
growth restriction. (73, 138) Our research did not support other researchers or our 
systematic reviews findings of an association with PE. Our systematic review showed a 
significant association between low PAPP-A with early and any onset PE. Previous 
research has shown a stronger association between low PAPP-A and early onset PE 
than late onset.(37) Studies on placental pathology have suggested that early onset 
disease is more likely to be associated with abnormal villous and vascular morphology 
whereas in late onset disease the placental morphology and histology are not dissimilar 
to those in controls.(139, 140)  There is evidence that late onset disease is more likely 
to be related to impaired glucose metabolism and a hyperdynamic low peripheral 
resistance maternal cardiovascular profile.  We showed a low PAPP-A to be 




Several previous studies have reported an association between increased 2nd 
trimester levels of β-hCG and adverse pregnancy outcomes including PE, SGA, 
preterm delivery and miscarriage. Other studies found that decreased levels in the 1st 
trimester were predictive of PE. (142) In our study abnormal 1st trimester levels of β-
hCG were not significantly associated with any of the outcomes we assessed 
supporting our systematic review findings and findings by Spencer (2005) and Smets 
(2008).(44, 99) hCG is produced by the syncitiotrophoblast of the placenta and consists 
of alpha and beta subunits. It has been postulated that low β-hCG between 10-14 
weeks may be a consequence of impaired placentation and a smaller placental mass 
and that subsequently high 2nd trimester levels may develop as a result of 
hypoperfusion–related stimulation. The increased hCG in PE may be associated with 
reactive hyperplasia of cytotrophoblastic cells and functional alteration of the 
syncitiotrophoblast leading to increased leakage into the maternal circulation.(142, 143) 
Our findings of no association between abnormal levels and adverse pregnancy 
outcome would support this hypothesis. 
 
Kisspeptin-54 (metastin) was first identified as a suppressor of tumour metastasis and 
has been described in abundance in the placenta. As levels rise dramatically from 8 
weeks gestation coinciding with the time of peak trophoblastic invasion it is thought to 
play a key role in implantation and development. A small study measured kisspeptin 
levels between 8-14 weeks of gestation and found that levels were lower in women that 
had SGA neonates. (44) A subsequent study measured kisspeptin levels at 16-20 
weeks gestation and looked at the association with SGA and PE and also found that 
kisspeptin levels were significantly lower indicating that kisspeptin levels are reduced in 
conditions associated with poor placentation. (45) These studies were retrospective 
case control and did not assess its use as a biomarker for PE in the 1st trimester. 
Kisspeptin and its association with PE were only assessed in the 2nd trimester study. 
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We had the opportunity to measure kisspeptin levels in a small sample of our study 
population due to a separate research collaboration. We did not demonstrate any 
significant association between low kisspeptin and any adverse outcomes. Although 
our study’s prospective it was hampered by a low prevalence of outcomes in the 
unselected population whom had kisspeptin measured. 
 
In order to properly assess the role of kisspeptin as a biomarker for PE and other 
adverse pregnancy outcomes secondary to poor placentation it would need to be 
performed on a larger scale, ideally on at least all of the women that were recruited. 
Limitations to measuring kisspeptin; mainly expense of the test and the need to 
process samples within minutes of being taken from the patient, will have huge 
implications on its suitability as a biomarker within a prognostic model that could be 
used routinely in the NHS and therefore it is highly unlikely that it would currently be 
implemented within such a screening tool.  
 
There was a significant association between a high mean UAD PI and MAP and PE but 
not PIH supporting previous findings. (47, 94, 144). Our study findings support previous 
findings by Khalil et al for the role of arteriography for predicting women at risk of 
hypertensive diseases of pregnancy demonstrated by a significant increase in 
augmentation index, SBPAO and MAP in our preeclamptic and PIH groups. We did not 
demonstrate any association between abnormal arteriography and SGA which is 
supported by previous research findings which did not demonstrate ay significant 
difference in haemodynamic parameters in SGA without associated PE.(145) Khalil 
suggests that in women with increased arterial stiffness and higher SBPAO, PE is not 
mediated by impaired placental perfusion and function. Unlike with UADs and 
biomarkers which have been shown to be more strongly associated with early onset PE 
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the effectiveness of arteriography is unrelated to gestational age at onset of disease. 
These findings support the concept of two separate pathophysiologies for the 
development of PE, one based on a predisposition to cardiovascular disease that 
under the physiological stress of pregnancy manifests as early or late PE, the other 
resulting in early PE due to impaired trophoblastic invasion of the maternal spiral 
arteries.(47) 
 
Despite one researcher recruiting a large number of diverse women there was a lower 
incidence than expected of the outcomes we were assessing in our study population. A 
power calculation was performed prior to study commencement (see appendix 5.4), 
and the number of women needed to gain statistical power were recruited, however the 
lower incidence than expected of the various outcomes we were assessing may have 




Our model demonstrates an improvement in the detection of preeclampsia from that of 
the NICE guideline which is currently used. Our findings do not support a role for the 
routine use of 1st trimester maternal serum biomarkers for predicting women at risk of 
hypertensive disease in pregnancy. However, my research does support previous 
findings in the role of PlGF and PAPP-A for predicting women at risk of having an SGA 
baby. (54, 141) PAPP-A is already routinely measured as part of the combined 
screening test and has been incorporated in to RCOG guidance on SGA. (53) 
Haemodynamics show a lot of promise for the prediction of hypertensive disease, from 
the findings of our study and Khalil’s. It is also inexpensive (after the initial purchase of 




The finding of high 1st trimester AFP levels in association with stillbirth raises the 
possibility of combining it with other biomarkers e.g. PlGF, and using it as a screening 
tool. The increased PlGF in association with stillbirth supports findings by Akolekar et 
al. (56) Markers can be used in conjunction with biophysical parameters, either 1st 
trimester or 2nd trimester Doppler.  
 
Our model measures variables reflective of placental function (PAPP-A, PlGF, β-hCG, 
kisspeptin) or increased resistance in the uteroplacental circulation (UADs), as our 
study had a very low incidence of early PE we combined all cases to form one group of 
any onset PE, as the majority of this group were made up of late onset cases this may 
explain why our study has not shown any association between 1st trimester abnormal 
biomarker levels and PE.  
 
Our study findings have been limited from the low prevalence of outcomes in our 
group. Larger studies are needed to clarify the efficacy of biomarkers in 1st trimester 
prediction models for PE. It is clear that the value of these markers is limited with late 
onset disease but show promise in terms of early onset and more severe forms of PE. 
Larger studies are needed to justify the introduction of these markers into routine 
clinical practice as part of a prediction model for preterm PE and then in screening for 
other uteroplacental problems. 
 
This is the first study that links a high 1st trimester AFP with stillbirth. Larger studies 










To validate the increasing number of prognostic models being developed for PE using 
our own prospective study. 
 
Methods 
A systematic review of literature that assessed biomarkers, UAD and maternal 
characteristics in the 1st trimester for the prediction of PE was performed and models 
selected based on predefined criteria. Validation was performed by applying the 
regression coefficients that were published in the different derivation studies to our 
cohort. We assessed the models discrimination ability and calibration. 
 
Results 
Twenty models were identified for validation from 11 studies. The discrimination ability 
observed in derivation studies (Area under the Curves) ranged from 0.70 to 0.96 when 
these models were validated against the validation cohort, these AUC varied 
importantly, ranging from 0.504 to 0.833. Comparing Area under the Curves obtained 
in the derivation study to those in the validation cohort we found statistically significant 





There currently isn’t a definitive prediction model with adequate ability to discriminate 
for PE, which performs as well when applied to a different population and can 
differentiate well between the highest and lowest risk groups within the tested 
population. The pre-existing large number of models limits the value of further model 
development and future research should be focussed on further attempts to validate 
existing models and assessing whether implementation of these improves patient care. 
 
Citation of paper arising from this work: 
Allen R, Zamora J, Arroyo-Manzano D, Velauthar L, Allotey J, Thangaratinam S, 
Aquilina J. External Validation of pre-existing first trimester preeclampsia prediction 
models. European Journal of Obstetrics and Gynecology and Reproductive Medicine. 















There has been a rise in the number of prognostic models being developed in 
obstetrics, particularly for PE, but few have been implemented. Risk assessment is 
currently performed at the booking appointment and is based on maternal 
characteristics alone. However this approach is thought to falsely classify two thirds of 
women as being high risk and in need of intensive monitoring and prophylactic aspirin 
therapy, highlighting the need for a better screening test.(5) 
 
Modern medicine is increasingly focussing on preventing disease. As a result it is 
important to identify patients at increased risk of illness. This could be based on a 
single risk factor or a combination of multiple predictors. Combining predictors into a 
prognostic model is likely to allow better risk assessment than the use of single risk 
factors.  
 
In recent years there has been a massive amount of studies published looking at 
various biophysical and biochemical markers alone or in combination for the prediction 
of PE. A recent systematic review by Kleinrouweler et al. identified 69 prediction 
models for PE, only 5 of which had been externally validated and model performance 
was found to be lower when externally rather than internally validated. They 
recommended that systematic reviews should be performed to identify and validate 
existing models to decide whether a new model should be developed or an existing 
model updated. Following this the better models should be applied in clinical practice 




As a result of this review we have decided to externally validate pre-existing PE models 
using data obtained from our own prospective study to predict PE risk. We focussed on 
1st trimester prediction models as interventions to reduce the risk of PE, mainly aspirin, 





To validate clinical prediction rule for PE from models reported in obstetric literature. 
(30, 36, 37, 76, 79, 146-151) 
 
Validation study population. 
The data from two cohorts of pregnant women attending the Royal London Hospital for 
their 1st trimester dating scan who were recruited for research into 1st trimester 
screening for PE over two time periods (2010-2012 and Jan 2013-July 2014) were 
combined. Women with multiple pregnancies and fetal anomalies were excluded. 
Ethics approval was obtained from the East of England research ethics committee. 
Information was collected on age, ethnicity, method of conception, parity, smoking, 
alcohol and drug use, past medical and obstetric history, family history and drug 
history. Maternal weight and height were measured and BMI calculated as was blood 
pressure and MAP. Transabdominal ultrasound was used to measure the uterine artery 
flow velocity waveforms with colour pulsed Doppler using a Voluson E6 with a 3.5/5 
MHz linear array, the method for which has previously been described in chapter 2.  





Prognostic models and study selection 
We searched Medline from inception until November 2016 without language 
restrictions. Full details of the search strategy are given in our previous paper.(50) 
Models were selected for validation if they met the criteria detailed in table 6.1. Models 
were excluded if they did not include 1 or more of the predictors and if they did not 
have a regression coefficient. 
 
Table 6.1: Selection criteria for inclusion in validation of prognostic models 
 
Quality Assessment of Prognostic Models 
The Quality in Prognosis studies (QUIPS) tool was used assess the risk of bias in the 
included prognostic studies. The bias domains assessed were study participation, 
attrition, prognostic factor measurement, confounding measurement and account, 
outcome measurement and analysis and reporting. Each domain was assessed as 
either low, high or moderate risk of bias. (65) 
Criteria  
Population Pregnant women in the 1st trimester 
Predictors Maternal clinical characteristics at booking – Maternal characteristics: 
Age, BMI, ethnicity, smoking, medical history particularly hypertension, 
diabetes, antiphospholipid syndrome or SLE.  
Previous obstetric history: parity, previous hypertensive disease, family 
history of PE, previous miscarriages,  stillbirth or SGA fetus; Current 
pregnancy: early pregnancy bleeding, systolic and diastolic blood 
pressure  
 
Biochemical markers (1st trimester)– PAPP-A, PlGF, AFP, HCG, 
kisspeptin 
Ultrasound markers (1st trimester)– UAD (resistance index, pulsatility 
index, unilateral or bilateral notching)  
 









We describe baseline characteristics of the validation cohort using median and 
interquartile ranges (IQR) and absolute and relative frequencies. We compared 
baseline clinical and demographic characteristics of the women recruited in the two 
cohorts used in the validation process. We used Mann-Whitney U tests and Chi-
squared tests or Fisher exact tests when needed for these comparisons. The 
comparison of both cohorts was further extended to evaluate the predictive 
performance of the models within the two groups of women included in the validation 
cohort. 
 
Validation of the models included in this review was performed by applying the 
regression coefficients that were published in the different derivation studies to our 
cohort. We obtained predicted probabilities of any PE for all models. Since the 
prevalence of PE in the derivation cohorts were slightly different to the validation one, 
we recalibrated the regression coefficients of the original models by computing a 
shrinkage correction coefficient. This allows adjustment of predicted probabilities to the 
prevalence of PE in the validation cohort. (152) We based all analyses on the shrunk 
probabilities.  
 
For every model, we assessed its discrimination ability and its calibration. We 
assessed discrimination ability computing the Area under the ROC curve. We 
compared AUCs in the validation cohort with the AUC reported by authors of the 
original models using a Z-test. (66) We evaluated model calibration by the Hosmer-
Lemeshow goodness-of-fit test.  
 
Predictive information of a model is the degree of separation of the predictive 
probabilities estimated for the highest and lowest risk of PE groups. We computed 
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PSEP statistic as the difference between the mean predicted probability of the high risk 
group (4th quartile) minus the mean predicted probability for low risk group (1st quartile). 
The higher the PSEP, the better the predictive information of the model.(153) 
 






We analysed 2,186 women. These women were obtained from 2 cohorts recruited over 
a 4 year period (2010-2014) at the Royal London Hospital. The incidence of PE was 
2.4% (n=52). The median age (IQR) was 29 years (26; 33), body-mass index 23.7 
(21.1; 27.0) kg/m2 and 802 (36.8%) had a BMI ≥25 kg/m2. 824 (37.7%) women were 
Caucasian, 233 (10.7%) Black, 117 (5.3%) Chinese, 942 (43.3%) Indian or Pakistani, 
64 (2.92%) mixed and 0.18% unknown. The population attending the Royal London is 
ethnically diverse with a large number of South Asian women. The high proportion of 
women recruited who were of a non-Caucasian ethnicity demonstrates that we 
managed to capture a large cross sample of our population which has hopefully 
avoided the introduction of bias.  
 
Among all analysed women we observed 17 (0.8%) who had previous PE, 25 (1.1%) 
had pre-existing diabetes mellitus, 21 (0.9%) history of hypertension, 426 (19.5%) had 
a family history of PE and 1006 (46.0%) were multiparous. Other variables are 




A comparison of the cohorts is shown in table 6.3.  We observed statistically significant 
differences in the median age (p<0.001), BMI (p=0.008), proportion of women with BMI 
≥ 25 kg/m2 (p=0.004) and in the proportion of women with a family history of PE 
(p<0.001) and previous PE (p<0.001) (table 6.3). 
 
Table 6.2: Baseline variables of validation cohort 





Age 1  2,180 29.00 (26.00; 
33.00) 
BMI 1  2,180 23.70 (21.10; 
27.00) 
FhCG1T 1 929 32.00 (21.60; 
49.90) 
PAPP-A (mIU/L) 1  929 3853 (2351; 6041) 
PAPP-A (MoM) 1  1,932 1.01 (0.69; 1.43) 
PlGF (pg/ml) 1  2,101 57.33 (43.60; 
78.37) 
PlGF (MoM) 1  2,082 1.00 (0.77; 1.34) 
MAP (mmHg) 1 2,186 84.00 (78.00; 
90.00) 
MAP (MoM) 1  2,179 1.00 (0.94; 1.07) 
Mean PI 1  2,186 1.45 (1.20; 1.72) 
Mean PI (MoM) 1  2,174 1.00 (0.84; 1.18) 
BMI (≥25 kg/m2) 2  2,180 802 (36.79%) 
Family Hx PE (Yes) 2  2,186 426 (19.49%) 
Diabetes Mellitus (Yes) 2  2,186 25 (1.14%) 
Multiparous (Yes) 2  2,186 1006 (46.02%) 
IVF(Yes) 2  2,186 36 (1.65%) 
Past PE (Yes) 3  2,186 17 (0.78%) 
Hypertension (Yes) 3  2,186 21 (0.96%) 
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Caucasian (Yes) 2 2,186 826 (37.79%) 
Black (Yes) 2 2,186 233 (10.66%) 
Other racial origin (Yes) 2 2,186 1127 (51.56%) 
Renal disease (Yes) 2  2,186 2 (0.09%) 
Thrombophilic condition 
(Yes) 2 
2,186 5 (0.23%) 
1 Reported as median (P25; 
P75) 
  
2 Reported as count (percentage)   
 
Table 6.3: Baseline variables comparison between validation cohorts 






Age 1  1138 29.00 (25.00; 
33.00) 
1042 30.00 (26.00; 
33.00) 
<0.001 
BMI 1  1137 23.88 (21.31; 
27.34) 
1043 23.53 (21.00; 
26.37) 
0.008 




(miU/L) 1  
- - 929 3853 (2351; 6041) - 
PAPP-A 
(MoM) 1  
1003 1.01 (0.67; 
1.45) 
929 1.02 (0.71; 1.42) 0.520 
PlGF (pg/ml) 
1  
1059 61.50 (46.72; 
85.20) 





1040 1.00 (0.78; 
1.30) 
1042 1.00 (0.75; 1.40) 0.685 
MAP 
(mmHg) 1 
1143 81.33 (75.00; 
86.67) 





1137 1.00 (0.94; 
1.07) 
1042 1.00 (0.93; 1.07) 0.539 
Mean PI 1  1143 1.45 (1.22; 
1.71) 
1043 1.47 (1.17; 1.74) 0.221 
Mean PI 
(MoM) 1  
1136 1.00 (0.86; 
1.19) 




kg/m2) 2  
1137 448 (39.40%) 1043 354 (33.94%) 0.008 
Family Hx 
PE (Yes) 2  
1143 413 (36.13%) 1043 13 (1.25%) <0.001 
Diabetes 
Mellitus 
(Yes) 2  
1143 14 (1.22%) 1043 11 (1.05%) 0.709 
Multiparous 
(Yes) 2  
1143 547 (47.86%) 1043 459 (44.01%) 0.071 
IVF (Yes) 2  1143 15 (1.31%) 1043 21 (2.01%) 0.198 
Past PE 
(Yes) 3  
1143 0 (0.00%) 1043 17 (1.63%) <0.001 
Hypertension 
(Yes) 3  
1143 11 (0.96%) 1043 10 (0.96%) 0.993 
Caucasian 
(Yes) 2  
1143 400 (35.00%) 1043 426 (40.84%) 0.005 
Black (Yes) 2 1143 125 (10.94%) 1043 108 (10.35%) 0.660 
Other racial 
origin (Yes) 2 
1143 618 (54.07%) 1043 509 (48.80%) 0.014 
1 U Mann-
Whitney 
N Median (P25; P75) N Median (P25; P75)  
2 Chi2 and 3 
Fisher exact 
test 
















Study selection  
























Full text articles assessed for eligibility: 
 (n=81) 
 ) 
Total Number of retrieved records 
 (n = 1008) 
 
Articles excluded after evaluation of 
abstracts: 
(n=927) 
Models included for validation: 
1st  trimester (n=20 from 11 studies) 
 
Models  excluded: 
(n=70) 
No regression coefficient (n=36) 
2nd trimester (n=7) 
Variables not measured (n=6) 
Duplicated data (n=6) 
High risk population (n=4) 
Nulliparous only (n=1) 
No prediction model (n=7 




Quality assessment was performed by two reviewers (JA) and (RA). There was a 
moderate risk of bias in the study participation domain for Akolekar but a low risk of 
bias for all the other domains and in all domains for the other studies. See table 6.4. 
 
Validation 
Models being validated are listed in Table 6.5. Sample sizes of these models ranged 
from 359 and 8,189 with prevalence of PE ranging between 0.4% and 14.7%. The size 
of the validation cohort depends on data availability for predictors included in the 
different models. So, sample size in this validation cohort ranges from 929 for the 
model of DiLorenzo 2012 (Early PE model) and 2,186 for DiLorenzo 2012 (Late PE 
model), Goetzinger 2010, Plasencia 2008 (Late PE model), Baschat 2014 (early PE 
model) and Poon 2009b (Early PE model) for which all available data is included in the 
analysis as no missing values are present for all predictors included in the models.  
 
The discrimination ability observed in derivation studies (AUCs) ranged from 0.70 
(Goetzinger 2010) to 0.96 (Scazzocchio 2013, Early PE model); when these models 
are validated in the validation cohort, these AUC varied importantly. AUCs ranged from 
0.504 (DiLorenzo 2012 Early PE model) to 0.833 (Poon 2009b Early PE model). When 
comparing AUCs obtained in the derivation study to those in the validation cohort we 
found statistically significant differences in several studies (Akolekar 2008 Early PE 
model, Plasencia 2008 Early and Late PE model, Poon 2009a Early and Late PE 
model, Poon 2009b Early PE model, Scazzocchio 2013, Early PE model, Baschat 2014 
early and late models).  
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Table 6.4: Quality assessment of the included studies 
Study   Bias 
Domains 


















Moderate  Low Low Low Low Low 
Plasencia 
2008 
Low Low Low Low low low 
Goetzinger 
2010 
Low Low Low Low Low Low 
DiLorenzo 
2012 
Low Low Low Low Low Low 
Poon 2008 Low Low Low Low Low Low 
Poon 2009a Low Low Low Low Low Low 
Poon 2009b Low Low Low Low Low Low 









Low Low Low Low Low Low 
Scazzocchio 
2013 
Low Low Low Low Low Low 
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Table 6.5: Summary of models and AUC-ROC comparison between derivation studies and validation study 
Study PE 
Screening 


























Early Case-control PlGF, PAPP-A 
UADs 















Late Case-control PlGF, UADs 






































UADs 2,060 13 
(6.3%) 












































UADs, BMI, ethnicity, 
previous history of PE, 












Poon, 2008 Overall Prospective 
cohort 
Ethnicity, BMI, 
previous hx PE, family 











Poon, 2009a Early Prospective 
cohort 
PAPP-A, UADS, 
ethnicity, history of 
chronic hypertension. 














Poon, 2009a Late Prospective 
cohort 
PAPP-A, ethnicity, 
BMI, previous history 












Poon, 2009b Early Prospective 
cohort 
UADs, MAP, ethnicity, 
history of chronic 
hypertension, previous 
history of PE, history 











Poon, 2009b Late Prospective 
cohort 
UADs, MAP, age,  
BMI, ethnicity, history 
of chronic 
hypertension, previous 
history of PE, family 











Poon, 2009c Early Prospective 
cohort nested 
in case-control 
PlGF, PAPP-A, UADs, 
BMI, previous history 
of PE, MAP 
7,538 34 
(0.5%) 






Poon, 2009c Late Prospective 
cohort nested 
in case-control 
PlGF, UADs, ethnicity, 
BMI, previous history 













Early Case-Control BMI, smoking, UAD PI 
































Parity, history of 
hypertension, renal 




















































Parity, history of 
hypertension, previous 














AUC-ROC: Area Under the Curve of Receiver Operating Characteristics  




Appendix 6.1 compares the AUC-ROC between the two validation cohorts that were 
combined. All the p-values, except for the Baschat study, are non-significant 
demonstrating that the models performance was the same when tested by two different 
validation cohorts from our hospital.  
 
The predicted probabilities of PE obtained after applying all models to the validation 
cohort are shown in table 6.6.  
 
Table 6.6- Estimated probabilities on validation’s cohort 
  Validation’s cohort 
Study PE 
Screening 








































































































































SD: Standard deviation 
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PSEP: Percentage of separation between the estimated mean of 4th and 1st quartiles of probabilities (Q1; 
Q4) and its means of probability 
Q1 and Q4: Means of probability of quartile 1st; and quartile 4th 
 
The overall mean probability of PE in the validation cohort ranges from 1.5 to 2.4%, 
reflecting the prevalence of PE in the cohort. PSEP statistic (the difference between the 
mean predicted probabilities in Q1 and Q4) was extremely low, ranging from as low as 
0.66% (Baschat 2014, early PE model) to 8.94% (Poon 2009c Early PE model) (Table 
6.6). Akolekar (Late PE model), Goetzinger 2010, Poon 2008, Poon 2009a (Late PE 
model), Poon 2009b (Late PE model), Poon 2009c (Late PE model), Baschat 2014 
(late PE model), Scazzocchio 2013 (late preeclampsia model) and Parra-Cordero 2012 
(early PE model) presented good calibration as assessed by Hosmer-Lemeshow 




A good prediction model should be highly discriminatory for the condition being 
predicted and there should be minimal difference between the expected and observed 
incidence of the condition when calibration is performed. 
 
Main Findings 
Our study has demonstrated poorer performance of the models for prediction of PE 
when applied to our external validation cohort. This difference was statistically 
significant in nine out of thirteen studies where we could compare the validation-
derivation AUCs (see Table 6.4).  All the derivation studies have reported AUCs that 
demonstrate that they have produced good models for predicting PE. However, when 
these models were applied to the validation cohort several were shown to perform 
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poorly (Di Lorenzo 2012, Early model, Goetzinger 2010, Plasencia 2008, Late, 
Scazzocchio 2013, late, Baschat 2014 early and late and Poon 2009a late) 
demonstrated by an AUC <0.7. On assessment of the calibration data the models that 
have assessed late or any onset of PE have calibrated better against the validation 
cohort with non-significant Hosmer-Lemeshow P values.   
 
The low PSEP statistic may reflect the low incidence of PE particularly in the validation 
cohort. It also indicates that the models were unable to identify what variables e.g. 
UADs, a particular biomarker or maternal characteristic, are key to predicting women at 
high risk of developing PE reflecting that a definitive 1st trimester predictive test has 
still not been found. The finding that the models have not performed as well when 
validated externally as internally is unsurprising and confirms previous findings by 
Kleinrouweler et al. and Oliveira.(50, 154)  
 
Models assessing early and late onset PE appeared to perform better for early PE with 
higher AUC values. This supports previous findings indicating two distinct 
pathophysiologies for early and late PE with early onset being associated with 
inadequate placentation and an imbalance between pro-and anti-angiogenic factors. 
Variables such as UADs and biomarkers would therefore be expected to perform better 
for early onset disease. The better calibration data for those models assessing late or 
any onset PE may be due to the higher incidence of late/any onset PE in the validation 
cohort. 
 
Some of the models performed significantly better than others. We examined the 
studies in greater detail to see if we could find an explanation for this. Akolekar, Parra-
Corderro and Goetzinger had a higher incidence of PE in their study population than 
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the other models and the validation cohort.(30, 69, 76) Goetzinger concluded that their 
model was only modestly effective in its predictive ability which was confirmed by our 
validation study. Di Lorenzo performed poorly with a low discriminative ability and poor 
calibration against the validation cohort. There was a low number of preeclamptics in 
the study population despite the large number of participants overall.(148) However 
these factors should not have caused a problem as we used an adjusted probability by 
the prevalence in each study. Plasencia and Baschat demonstrated lower AUCs in the 
validation cohort and performed significantly worse for both early and late PE with poor 
calibration.(146, 150) There was a comparable incidence of PE and overall study 
participants to the validation cohort however the ethnicity of the women was different, 
with a three times greater number of Afro-Caribbeans than the validation cohort. There 
were also a higher proportion of women with pre-existing chronic hypertension in the 
Baschat study.(150) The Poon studies had a large number of participants and a similar 
incidence of PE as the validation cohort.(36, 37, 79) There seems to be an improved 
detection rate with an increase in the number of variables included in the model. With 
Poon 2009c appearing to perform best.(37) This confirms previous conclusions made 
by Oliveira and Farina et al. (154, 155) 
 
There have been a small number of other studies that have attempted to externally 
validate PE prediction models. These studies have also been limited by small numbers 
of preeclamptics as in our own study. Park et al. validated the Fetal Medicine 
Foundation multiple logistic regression algorithm in an Australian population. They 
concluded that the FMF algorithm could effectively be applied to their population. 
However they reported that their findings were limited by the low number of women 
whom developed early PE.(156) Skrastad et al. also externally evaluated the FMF 
algorithm and the PREDICTOR model by Perkin Elmer. They excluded multips and 
women who were taking aspirin or anticoagulants. They concluded that both models 
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had a similar, but only modest performance in their prediction of PE. Their validation 
population was also limited by the low number of early preeclamptics; they defined 
early PE as delivery before 37 weeks which differs from that of 34 weeks used by the 
majority of studies. They reported that they only had 1 preeclamptic requiring delivery 
before 34 weeks which led to them omitting three of the seven risk estimates of the 
PREDICTOR model. This study was also limited by the relatively small study 
population (520 compared to 2186 in our study sample).(157) The ethnic make-up of 
the included women varies considerably from our study population and this highlights 
the value of externally validating models in several different populations. Oliveria et al. 
used data from their prospective observational study to validate 8 PE prediction 
models. Their findings were comparable to ours. They found 7 of the 8 models 
underperformed when applied to their population.(154) 
 
Oliveira were surprised to find that the predictive accuracy of 1st trimester PE 
prediction models was not better when there was a higher population prevalence of PE. 
They suggest that pre-test probability of PE plays a minor role in the predictive 
accuracy of multimarker algorithms.(154) This reassures us that these prediction 
models should be able to be applied to our population that has a relatively low 
incidence of PE.  
 
Strengths and limitations 
The strengths of our study include the large number of women prospectively recruited 
over a four year time period and the measurement of many variables which enabled us 
to use our data to validate a large number of pre-existing models. We have done a 
thorough statistical analysis comparing discriminatory and calibration data. Brunelli et 
al. performed a systematic review assessing the quality of 1st trimester prediction 
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models for PE. They found frequent methodological deficiencies which may limit their 
reliability and validity. The main issues highlighted were lack of external validation of 
models and overfitting where the number of events per variable is fewer than the 
commonly recommended 10 events per predictor. In their data all but one prediction 
model for early PE was based on a sample with less than 10 events per predictor. A 
low event per predictor rate may bias correlation coefficients of the model both 
positively and negatively affecting the interpretation of their performance.(158) Oliveira 
also commented on overfitting as a possible explanation as to why the models they 
assessed didn’t perform as well when externally validated.(154) A more conservative 
approach, such as ours, which shrinks the parameter estimates toward 0 and cross 
validates model prediction in patient subsets has been found to produce better 
performing models.  
 
Some of the models found in our search were excluded from our study as the actual 
prognostic model was not reported in the published paper and we could therefore not 
apply it to our population. The low incidence of PE in our validation cohort of 1.51-
2.41%, and as a result, not differentiating between early and late onset PE, unlike 
many of the models, may have affected our evaluation of their performance. However 
the incidence of PE in our population is similar to that in the Poon studies, which from 
our validation, have demonstrated better discriminatory and calibration data and higher 
PSEP values than the other models. The Poon model may also perform better when 
applied to our population than some of the other models as it was developed in a 







Our validation study has demonstrated that there doesn’t appear to currently be a 
definitive PE prediction model with adequate ability to discriminate for the condition, 
which performs as well when applied to a different population and can differentiate well 
between the highest and lowest risk groups within the tested population. The already 
large number of models assessing various variables alone or in combination limits the 
value of further development of models and further research would be better focussed 
on further attempts to validate existing models and assessing whether implementation 
of the models improves patient care. Evaluation of the models performance may be 
different if applied to a different cohort. Randomised trials could be performed 
allocating one group of women to intervention based on the standard risk assessment 
of PE based on NICE guidelines and the other to intervention based on predicted risk 
following application of the prognostic model. Outcomes in the different groups could 
then be measured to see if they were improved in those whom the prognostic model 
was applied. Some of the models we assessed were excluded from our study as the 
actual prognostic model was not reported in the published paper. Consensus based 
guidelines have been published recently advising authors on issues to report when 
developing a model. It is important that any future published models present their 











Chapter 7: Effect of diet and life style based metabolic risk modifying 




To evaluate the effect of dietary and lifestyle interventions with the potential to modify 
metabolic risk factors on the risk of PE. 
 
Methods 
 We searched MEDLINE, EMBASE and Cochrane from inception until February 2013. 
Randomised trials in pregnant women evaluating the effect of dietary and lifestyle 
interventions with the potential to modify metabolic risks such as obesity, 
hyperlipidaemia, hyperglycaemia and hypertension on the risk of PE were included. 
Two independent reviewers selected studies, extracted data and assessed quality. 
Results were summarised as pooled relative risks (RR) for dichotomous data.  
 
Results 
Eighteen studies (8712 women) met our search criteria for inclusion. Six studies 
evaluated diet (2695 women), six studied mixed interventions with diet, physical activity 
and lifestyle (1438 women) and six assessed essential fatty acid supplementation 
(4579 women).  The interventions overall reduced the risk of PE (RR 0.81, 95% CI 
0.69, 0.94; p=0.006 I2=0%) compared to the control group. Dietary interventions 
reduced the risk of PE by 33% (RR 0.67, 95% CI 0.53 to 0.85; p=0.001; I2=0%). There 
was no reduction in the risk of PE with mixed interventions (RR 0.93, 95% CI 0.66 to 
1.32, p=0.68, I2=0%) or fatty acid supplementation (RR 0.92, 95% CI 0.71 to 1.18; 
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p=0.49, I2=15%). Meta-regression showed a borderline impact of gestational diabetes 
status (p=0.05) on the observed effect. 
 
Conclusion 
Dietary and lifestyle interventions have the potential to reduce the risk of PE. The effect 
of additional therapeutic interventions in women with GDM on PE is not known.   
 
Citation of paper arising from this work: 
Allen, R., Rogozinska, E., Sivarajasingam, P., Khan, K. S., & Thangaratinam, S. 
(2014). Effect of diet‐and lifestyle‐based metabolic risk‐modifying interventions on PE: 















PE remains a leading cause of maternal deaths worldwide (1) and in developed 
countries, it is the main cause of maternal admissions to intensive care. (159) It is also 
associated with an increased risk of perinatal mortality and is the cause of 
approximately 10% of stillbirths and 15% of preterm births.(160, 161)  Obesity, 
dyslipidaemia, diabetes and hypertension are independent risk factors for PE.(162) PE, 
characterised by insulin resistance, widespread endothelial damage and dysfunction 
and increased systemic inflammatory response, shares metabolic risk factors with 
cardiovascular diseases such as myocardial infarction, stroke and death in the long 
term. (163) A systematic review has shown that higher levels of serum triglycerides was 
associated with, and precedes the onset of PE.(164)   
 
Interventions that reduce cardiovascular events by modifying metabolic risk factors also 
have the potential to reduce the risk of PE.  Currently, low dose aspirin, recommended 
as a prophylactic measure has been shown to reduce PE risk by 10%.(43, 165) 
Interventions based on diet and lifestyle are effective in reducing gestational weight 
gain with potential to reduce other adverse outcomes such as PE and gestational 
diabetes.(166) A large Norwegian observational study of 23,000 pregnant women 
showed that the risk of PE was reduced by a third in women on a diet rich in 
vegetables, vegetable oil, fibre and fruits by comparing them to women with a high 
intake of processed meat, salty snacks and sweet drinks. (167)The risk of PE is 
increased by 2.9 times in obese women compared to those of normal weight, and the 
odds were increased by 7, when the systolic blood pressure was measured on the 




Our previous review on weight management interventions in pregnancy had a narrow 
focus on gestational weight gain and PE. (166) Given the association of PE with 
metabolic risk factors such as raised lipids and blood sugar, we have widened the 
scope of our research question.  We undertook a systematic review to collate the 
evidence on the effect of non-pharmacological metabolic risk modifying interventions in 




We carried out a systematic review with a prospective protocol in line with current 
recommendations and PRISMA guidelines.(59) We searched Cochrane, Embase and 
Medline databases from database inception up to February 2013 to identify relevant 
citations. The search was undertaken in two steps. First, we updated our previous 
search on diet and lifestyle interventions in pregnancy to identify relevant new papers 
published until 2013. (The search strategy and search terms have been published 
previously). (9) Next, we undertook a separate search to identify studies that evaluated 
other relevant interventions that influence metabolic risk factors such as essential fatty 
acids and fibre. 
 
Identification of Studies 
We used the following search terms for the intervention (diet, fiber, dietary fibre, bran, 
isaphagula husk, methylcellulose, psyllium, fatty acids, fish oil, exercise) and combined 
with those for outcomes (preeclampsia, pre-eclampsia, PIH, gestational hypertension, 
hypertension). (The full search criteria is given in appendix 7.1). Reference lists of all 
known primary and review articles were examined to identify cited articles that were not 




Study selection and data extraction 
Randomised controlled trials in pregnant women evaluating the effect of dietary and 
lifestyle interventions with the potential to modify metabolic risks such as obesity, 
hyperlipidaemia/glycaemia and hypertension on the risk of PE were included. Study 
selection was performed in two stages. Interventions that included both diet and 
physical activity with or without behavioural modification were considered to be lifestyle 
interventions. We excluded non-randomised and animal studies. Firstly the electronic 
searches were scrutinised and appropriate studies were identified by two reviewers 
(RA and SS). Secondly, the two independent reviewers reviewed the full text of the 
identified papers and selected the studies that fulfilled the inclusion criteria. Any 
disagreements were resolved by discussion with a third reviewer (ST). Data were 
extracted, in duplicate, by dual teams of two independent reviewers (EA, ST; and RA, 
SS) in 2x2 tables for the effect of intervention on PE.  
 
Quality assessment of the included studies 
We evaluated the quality of the selected studies based on accepted contemporary 
standards.(59)  The risk of bias of the individual studies was assessed in six domains: 
sequence generation, allocation concealment, blinding, incomplete outcome data, 
selective outcome reporting and other potential sources of bias.  
 
Data Synthesis 
Results were summarised as pooled relative risks (RR) with 95% confidence intervals 
(CI) for dichotomous data. The treatment effects of the studies were pooled separately 
for the various intervention subgroups. Heterogeneity of treatment effects was 
evaluated graphically with forest plots and if substantial heterogeneity was noted (I2 
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>50%) possible causes were explored. To explore for sources of clinical heterogeneity 
we took into consideration the type of intervention and body mass index as explanatory 
variables. Additionally, we examined the impact of study quality on estimation of effect 
according to individual quality items (random sequence generation, allocation 
concealment, performance bias, detection bias and attrition bias). We initially 
performed univariable meta-regression analyses followed by multivariable analysis, 
which controlled for confounding among variables. Sensitivity analysis was performed 
by excluding studies on women with diabetes in pregnancy.  
 
We explored for publication bias by producing funnel plots which were tested for their 
asymmetry using Harbord’s test. All analyses were carried out with Revman 5.0 and 




Study selection  
We included 18 randomised trials (8712 women) from a total of 202 citations (Fig 7.1). 
Of these, 173 studies were identified from our search on metabolic risk factor modifying 
interventions such as fibre and essential fatty acids. A further 29 studies were obtained 
by updating our previous  search on diet and lifestyle based interventions (166). From 
the 202 papers evaluated, we included 18 studies (8712 women) in the review (Fig. 
7.1) (169-185) Six studies (2695 women) (169, 171, 177, 178, 182, 183) evaluated 
mainly diet based interventions, six (1438 women) (170, 172, 179, 180, 185, 186) 
studied mixed interventions such as diet, physical activity and lifestyle and six (4579 
women) (173-176, 181, 184, 187) studied lipid lowering agents such as essential fatty 
acids. The main reasons for exclusion of studies were inappropriate study design or PE 
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not assessed as an outcome (Fig 7.1). No RCTs examined the effect of only physical 
activity on the risk of PE.  
 


















Search results combined from databases: 
Medline, Embase, Cochrane 
(fibre, essential fatty acids, exercise) 
  (n = 173) 
Relevant papers found from a 
previous search that was 
updated13 (diet and lifestyle)  
(n =12) 
 
Total number of retrieved records 
(n = 202) 
 
Articles excluded 
(n = 58) 
 
Inappropriate population (n= 3) 
Inappropriate outcome (n=17) 
Inappropriate intervention 
(n= 5) 
Inadequate study design (n=21) 
No full text available (n =7)  
Correspondence only (n= 5) 
 
Randomised controlled trials: 18 (8712 women) 
Essential fatty acids=6 (4579) Mixed=6 (1438) Diet=6 
(2695) 
Articles excluded after 
evaluation of abstracts 
(n =126) 
 
Full-text articles assessed for eligibility 
(n = 76) 
Relevant citations found from 




Quality of the included studies 
The quality of the included studies is shown in Fig 7.2. Sequence generation was low 
risk in 89% (16/18) of the studies and unclear in the remaining 11% (2/18).  Allocation 
concealment was low risk in 50% (9/18), high risk in 6% (1/18) and unclear in 44% 
(7/18). The risk of selective reporting was low risk in 72%, high in 11% and unclear in 
17%. Performance bias was low risk in 33% (7/18) and unclear in 67%. The risk of bias 
for blinding in objective outcome assessments was unclear in thirteen (10/18, 55%) of 
the studies. 17 (94%) studies adequately addressed the problem of incomplete 
outcome data. 
 
Fig 7.2: Quality of RCTs included in systematic review 
 
 
Characteristics of the included studies 
The included studies comprised of women with various body mass index (BMI). Seven 
studies included mainly obese women (BMI≥30 kg/m2).(170-172, 178, 182-184) Ten 
studied women with any BMI.(169, 174-177, 179-181, 184, 186) Maternal weight was 
not specified in one study. (173) The effect of interventions was evaluated on pregnant 
women at risk of gestational diabetes mellitus in three studies.(169, 178, 182) In two of 
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the studies that included women with GDM, insulin was prescribed as an adjunct to diet 
and lifestyle in 7.8% and 20% of women in the intervention group and 0.4% and 3% of 
women in the control group respectively.(169, 178) None of the women in the mixed or 
essential fatty acids intervention groups had impaired glucose tolerance. Three of the 
studies (50%) in the mixed intervention group included mainly obese women. Seven 
studies assessed the effect of interventions in women with no pre-existing risk factors 
for the development of PE.(170, 174, 177, 179, 181, 182, 186) Three in women with 
risk factors which included previous pregnancies affected by IUGR, PIH, PE, stillbirth or 
abnormal UAD measurements in the index pregnancy. (173, 175, 176) Eight studies 
did not report the risk status of the participants.  
 
The diet based interventions included an energy restricted or cholesterol lowering diet, 
healthy dietary advice provided by a trained nutritionist and use of food diaries. Six 
studies assessed a combination of both diet and lifestyle such as dietary guidance, 
gym membership and personalised graphs of weight gain during pregnancy. The lipid 
lowering agents included essential fatty acids such as fish oil and gamma linoleic acid. 
Five studies examined fish oils (eicosapentanoic acid and/or docosahexanoic acid) 
alone and one study looked at docosahexanoic acid in combination with gammalinoleic 
acid. (173) The control group included women who were provided routine antenatal 
care. The interventions were commenced in the 1st trimester in seven studies 
evaluating mixed interventions (n=5) and essential fatty acids (n=2); (172, 173, 179, 
180, 184-186) in the 2nd trimester in ten studies  on interventions such as diet (n=5) 
and essential fatty acid (n=5) (169, 171, 175-177, 179, 181-184); and in the third 
trimester in one study with essential fatty acids (174) that was continued until delivery. 
In two studies, in diet (n=1) and mixed (n=1) group, the intervention was commenced in 
any trimester (see appendix 7.2). (170, 178) 
134 
 
Effect of interventions on PE 
The interventions significantly reduced the risk of PE (RR 0.81, 95% CI 0.69 to 0.94; 
p=0.006) compared to the control group with no heterogeneity (I2= 0%) (Fig 7.3). 
Amongst interventions, those based mainly on diet showed a significant reduction in 
PE by 33%, compared to the controls (RR 0.67, 95% CI 0.53 to 0.85; p=0.001) with no 
heterogeneity (I2=0%). Pooled estimate of the six studies on mixed interventions (diet 
and lifestyle) did not show a difference in the rates of PE between the two groups (RR 
0.93, 95% CI 0.66 to1.32, p=0.68; I2=0%). There was no significant reduction in PE 
(RR 0.92, 95% CI 0.71 to1.18; p=0.49, I2=15%) in women on essential fatty acids.  
Sensitivity analysis after excluding women with gestational diabetes showed that the 
reduction in PE did not persist by combining all interventions (RR 0.91, CI 0.75, 1.11, 
p=0.37) or in the diet only group (RR 0.86, 95% CI 0.45, 1.64, p=0.64). Sensitivity 
analysis after excluding studies where the intervention was commenced after the 1st 
















Meta-regression analysis did not show any significant impact of explanatory variables 
such as the type of intervention (p=0.11) BMI category (p=0.39), or components of 
study quality on the effect of interventions on the risk of PE. A borderline significance 
(p=0.05) was observed for gestational diabetes (Table 7.1). Harbord’s test for funnel 








Table 7.1: Exploration of heterogeneity in estimation of effect of diet and life style 
based metabolic risk modifying interventions on PE (univariable analysis) 
 
Heterogeneity outcomes Coefficient (SE) P - value 
Clinical features   
Intervention type (diet vs mixed 
vs fish oil) 0.18 (0.11) 0.11 
BMI category (mixed vs 
overweight & obese)# -0.18 (0.21) 0.39 
DM status (diabetic vs healthy) 0.35 (0.17) 0.05 
Study quality   
Random sequence generation* 0.31 (0.16)   0.07 
Allocation concealment 0.10 (0.19) 0.60 
Performance bias 0.13 (0.20) 0.53 
Detection bias 0.27 (0.17) 0.13 
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Attrition bias 0.26 (0.16) 0.13 
* mm (method-of-moments) estimate used for estimation of between study variance 






Dietary and lifestyle interventions in pregnancy may reduce the risk of PE. Amongst 
interventions, those based on diet were more effective in reducing the risk compared to 
mixed interventions or with essential fatty acid supplementation in pregnancy. It is likely 
that this benefit was driven by studies on women with GDM. 
 
The reduction in PE was observed with diet based intervention and not with mixed diet 
and physical activity based intervention. This could be due to the increased compliance 
with a simple intervention with one component compared to a complex intervention 
incorporating diet and physical activity. (166) Unfortunately, we were unable to 
compare compliance between groups as this data was not reported by the majority of 
the studies. Where it was reported (three of the essential fatty acids studies and three 
of the mixed group studies) the actual number complying with the intervention was not 
given in the majority of cases but was reported to be similar between groups.  The risk 
of PE is known to be reduced by a third with a healthy balanced diet comprising 
vegetables, compared to a diet predominantly on processed food. (167) An increase in 
dietary total fibre intake reduces the level of triglycerides which in turn is associated 
with a reduction in PE. (188) It has also been shown that diets based on low fat meat 
and dairy products, whole grains, fruit, vegetables and fish from second  trimester until 
delivery is effective in reducing maternal total and low density lipoprotein (LDL) 




The studies that evaluated dietary intervention were comprised mostly of women with 
pre-existing metabolic risk factors such as obesity and impaired glucose tolerance, 
compared to the other studies. The combination of less weight gain and better 
glycaemic control may have contributed to the reduction in PE. Existing randomised 
evidence do not suggest a significant association between reduction in gestational 
weight gain and lowered risk of PE (189) The reduction in PE was not observed after 
excluding studies with GDM, suggesting a significant role for glycaemic control on the 
outcome.   
 
Fish oil with eicosapentanoic acid and docosahexanoic acid, increase the peroxismal 
β-oxidation of fatty acids and reduce hepatic fatty acid production, thereby reducing the 
availability of substrates for triglycerides. Although in the non-pregnant state, 
supplementation with fish oil is known to significantly reduce the levels of triglycerides 
and cholesterol in both normal and dyslipidaemic population, this reduction was not 
observed in pregnancy supplemented with fish oil after 20 weeks of gestation. (190) It 
is possible that the absence of beneficial effect of omega 3 fatty acids in reducing PE is 
due to its ineffectual action on metabolic risk factors in pregnancy.  Although both 
essential fatty acids and mixed intervention subgroups did not show any beneficial 
effect, the type of intervention did not have a significant impact on the outcome as 
shown by our meta-regression. 
 
Our review is the first, to our knowledge, to specifically evaluate the role of dietary and 
lifestyle interventions with potential to modify metabolic risk factors on the risk of PE. 
We undertook a detailed search strategy and captured the relevant studies without any 
language restrictions. We have provided the clarity necessary to judge the effects of 
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the interventions by assessing the quality of the individual studies. The findings were 
limited by the variation in the components, intensity, compliance, timing and delivery of 
complex interventions such as those based on diet and mixed type. The studies on 
essential fatty acids varied in the dose and type of fatty acid supplementation, the 
baseline levels of n-3 fatty acids in the participants, and the duration and timing of the 
supplementation. No studies performed a direct comparison of the various 
interventions, thereby restricting the ranking of interventions based on effectiveness. 
The studies did not always report the effect of intervention on all the relevant metabolic 
risk factors such as gestational weight gain, gestational diabetes and lipid levels.  
 
The two studies on women with gestational diabetes had additional intervention such 
as insulin. Although, both randomised groups received insulin, the proportion in the 
intervention group was higher than the control group in both studies.  Hence, we 
cannot rule out the possibility that insulin use could have been an important contributor 
to the beneficial effect observed.  
 
We restricted our systematic review to those interventions that had a proven role in 
reducing underlying metabolic risk factors. Inclusion of other interventions such as zinc 
and calcium, that have a potential modifying effect on risk factors, could have led to a 
different conclusion. Although serum zinc levels were lower in women with PIH, there is 








There is a need to evaluate the effect of dietary interventions in women with pre-
existing metabolic risk factors on PE. A large randomised trial involving women with 
metabolic risk factors will quantify the effect of diet based intervention with precise 
estimates. There is a scope for further research on the effect of the interventions that 
modify metabolic factors such as lipid levels, blood pressure and glycaemic control on 
PE.  Individual patient data meta-analysis of interventions of published trials will allow 
us to evaluate the differential effects of the intervention in various subgroups of women, 
and to undertake additional analysis by excluding women with added interventions 
such as insulin. The optimal timing, components of the dietary intervention, mode of 














Chapter 8: Conclusion 
 
Section 8.1 Summary of Findings 
 
This chapter summarises the results of the individual chapters. Detailed results are 
provided in each individual chapter. The table below is the table of my research 
objectives given in the introduction chapter with an additional column which includes a 




Table 8.1 Structured questions of the chapters of the thesis with results 
Chapter 
Number 





Objective A:  To determine the accuracy of biomarkers for the prediction of 












Serial levels of 
PlGF and AFP at 












No significant association found between any of the 
biomarkers and PE/PIH or gestational diabetes mellitus. 
Low PAPP-A and PlGF were significantly associated with 
SGA <10th centile (p=0.007 and 0.004 respectively). High 
AFP (p=0.041) and low PlGF (p=0.036) were significantly 
associated with stillbirth. There was a significant 
association between low serial PlGF levels and SGA<5th 
(p=0.037) and 10th centiles (p=0.014). No association 
between serial AFP levels and any of the outcomes.  
Objective B: To determine the accuracy of UADs for the prediction of PE and 

















Increased mean UAD PI (1.08 MoM) was significantly 




Objective C: To evaluate the predictive value of maternal characteristics and 





















Aix (p<0.027), SBPAO (p=0.002) MAP (p=0.014), Afro-
Caribbean ethnicity (p=0.013) and a history of 
hypertension (p=0.047) were significantly associated with 
the development of PE. SBPAO (p=0.015), MAP 
(p=0.001) and maternal weight (p=0.001) were the only 
parameters significantly associated with PIH. All 
haemodynamic parameters were not significantly 
associated with SGA <10th or 5th centiles. Maternal 
hypertension was significantly associated with SGA <10th 
centile (p=0.03). For SGA<5th centile there was a 
significant association with South Asian ethnicity 
(p=0.047) and maternal smoking (p=0.018). Maternal 
smoking was significantly associated with stillbirth 
(p=0.025). The haemodynamic parameters augmentation 
index, pulse wave velocity, MAP and SBPAO were 
significantly associated with GDM (p=0.025, 0.048, 0.007 
and 0.019 respectively) along with maternal South Asian 
or Oriental ethnicity (p=<0.001 and 0.024). 
Objective D: To validate pre-existing PE models  
 Pregnant 
women in the 





PE Review of pre-
existing PE 
models  and 
validation of 
data with my 
primary study 
data 
The validation cohort included 2186 women. The 
incidence of PE was 2.4%. Fourteen models were 
identified for validation. Sample sizes of these models 
ranged from 638 and 8,189 with prevalence of PE 
ranging between 0.4% and 13.9%.The discrimination 
ability observed in derivation studies (Area Under the 
Curves) ranged from 0.70 to 0.954 when these models 
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were validated against the validation cohort, these AUC 
varied importantly, ranging from 0.504 to 0.833. 
Objective E: To perform systematic reviews assessing the effectiveness of 
biomarkers, UADs and diet and lifestyle interventions in the prediction and 
prevention of PE and other adverse pregnancy outcomes 
 
 Pregnant 








1071 citations, 30 studies included in the systematic 
review. Markers assessed were PAPP-A, PlGF, PP13, β-
hCG, soluble endoglin, inhibin-A, pentraxin, p-selectin, 
VEGF and sflt-1. Abnormal 1st trimester maternal 
biomarkers and PE of any onset were reported in 24 
studies which included 61,745 women. Abnormal levels 
of the biomarkers PAPP-A (9 studies; OR 2.1, 95% CI 
1.6, 2.6, I2 45%), PP13 (4 studies; OR 4.4, 95% CI 2.9, 
6.8, I2 50%), sFlt-1 (4 studies; OR 1.3, 95% CI 2.9, 6.8, I2 
27%), pentraxin (1 study; OR 5.31, CI 1.9, 15.0) and 
inhibin-A (3 studies; OR 3.57, 95% CI 1.7, 7.6, I2 21%) 
were significantly associated with development of any 
PE. Ten studies (15,760 women) evaluated six 
biomarkers with the development of PE before 34 weeks 
of gestation. PlGF (4 studies; OR 3.4, 95% CI 1.6, 7.2, I2 
87%),   PAPP-A (5 studies; OR 4.8, 95% CI 2.5, 22.5, I2 
72%), PP13 (5 studies; OR 7.5, 95% CI 2.5, 22.5, I2 
69%), soluble endoglin (2 studies; OR 18.5, 95% CI 8.4, 
41.0, 14%) and inhibin-A (1 study; OR 4.1, 95% CI 1.9, 
8.8) were significantly associated with early onset PE. 
The relationship of late onset PE and abnormal 
biomarker levels was evaluated in seven studies (12,053 
women), examining five biomarkers. A significant 
association was seen for soluble endoglin (3 studies; OR 
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2.1, 95% CI 1.9, 2.4, I2 0%) and inhibin-A (2 studies; OR 
1.9, 95% CI 1.4, 2.8, I2 0%). 
 Pregnant 
women in the 







340 citations.  After screening, 13 2nd trimester studies 
(n = 85,846) including 508 stillbirths, and two 1st 
trimester studies (n=9935, 66 stillbirths), were included in 
the systematic review. The sensitivity of UADs in the 2 
individual studies ranged from 14.5-100%. The specificity 
ranged from 64-91%. Due to the limited number of 
studies and participants and the high heterogeneity 
observed we could not obtain a pooled estimate of 
sensitivity and specificity. For 2nd trimester studies the 
bivariate pooled estimate for sensitivity was 65% (95% CI 
38 –85%) and for specificity, it was 82% (95% CI 72– 
88%). The positive was 3.5 (95% CI 2.3 –5.5) and 
negative LR 0.43 (95% CI 0.22 – 0.85). The diagnostic 
odds ratio (DOR) was 8.3 (95% CI 3 – 22.4). Subgroup 
analysis of the high risk group (n=6) showed that the 
average sensitivity was 90% (95% CI 36 – 99 %) with a 
pooled specificity of 69% (95% CI 54 – 81%). The 
positive LR was 2.9 (95% CI 1.8 – 4.9), negative LR 0.14 
(95% CI 0.1 – 1.8) and diagnostic OR 21.3 (95% CI 1.2 – 
380). In the seven 2nd trimester studies that performed 
UAD in an unselected population Pooled sensitivity is 
46%, (95% CI: 32 – 60%), pooled specificity is 88% (95% 
CI: 82 – 93%). The positive LR was 3.96 (95% CI: 3.1 – 
5.0), negative LR 0.62 (95% CI: 0.50 – 0.75) and 




 All pregnant 
women 










18 randomised trials (8712 women) from a total of 202 
citations included. . Six studies evaluated diet (2695 
women), six studied mixed interventions with diet, 
physical activity and lifestyle (1438 women) and six 
assessed essential fatty acid supplementation (4579 
women).  The interventions overall reduced the risk of PE 
(RR 0.81, 95% CI 0.69, 0.94; p=0.006 I2=0%) compared 
to the control group. Dietary interventions reduced the 
risk of PE by 33% (RR 0.67, 95% CI 0.53 to 0.85; 
p=0.001; I2=0%). There was no reduction in the risk of 
PE with mixed interventions (RR 0.93, 95% CI 0.66 to 
1.32, p=0.68, I2=0%) or fatty acid supplementation (RR 
0.92, 95% CI 0.71 to 1.18; p=0.49, I2=15%). Meta-
regression showed a borderline impact of gestational 




Section 8.2 Strengths and Limitations 
 
Systematic reviews were performed with robust methodology. Extensive literature 
searches were performed without language restrictions to avoid missing any studies 
and reference lists of articles were checked to identify any relevant studies not 
captured by electronic searches. Authors were also contacted if the relevant data was 
not reported. Predefined data extraction forms were used and data was extracted in 
duplicate by two reviewers. Any disagreements were discussed with a third reviewer. 
Rigorous assessment of the quality of included studies was performed using the 
recommended assessment tools.  
 
The biomarker review was the first review to provide summary estimates of the 
association between abnormal 1st trimester maternal blood biomarkers and PE. 
Previous reviews have not quantified the strength of association for all relevant 
biomarkers limiting direct comparison of the markers and have only assessed four 
biomarkers from any trimester of pregnancy. However, the review was limited by the 
amount of heterogeneity and the need to exclude several studies from analysis due the 
way the results were reported and suitable results not being provided by authors 
despite contacting them. 
 
The stillbirth review was also limited by high heterogeneity and the large variation 
between the UAD parameters measured and the thresholds used. As our literature 
search only revealed two 1st trimester studies, our analysis was limited for this 
subgroup and more in depth for the 2nd trimester studies. This review was also 




In our prevention review we explored for possible sources of heterogeneity such as 
type of intervention and BMI. We examined the impact of study quality on the 
estimation of effect according to individual quality items. Multivariable analysis was 
performed after univariable analysis to control for any confounders. Sensitivity analysis 
was performed excluding studies in women with GDM and publication bias explored. 
The use of insulin in two of the diet studies with women with GDM and the higher 
incidence of the use of insulin in the intervention group meant that insulin could have 
contributed to the beneficial effect observed.  
 
The validation study was the first to evaluate several 1st trimester prediction models. 
Thorough statistical analysis was performed. Two validation cohorts, recruited by two 
different researchers, from the same patient population were compared and 
assessment of the models performance was the same supporting the overall findings. 
The low incidence of PE in the validation cohort leading to early and late cases being 
combined may have affected evaluation of the models performance.  
 
A large number of unselected women were recruited in our primary study and 
previously unpublished variables were assessed e.g. AFP. A major limitation was the 
low incidence of early PE (one case) leading to all cases of PE being combined. As it is 
likely that there are two different pathophysiologies for early and late disease this is 







Section 8.3 Implications for Clinical Practice 
 
The finding of high 1st trimester AFP levels in association with stillbirth raises the 
possibility of combining it with other biomarkers e.g. PlGF, and using it as a screening 
tool. If 1st trimester levels were elevated these women could go on to have 2nd 
trimester UAD parameters measured and if positive serial growth scans and placental 
and fetal Dopper measurements performed. The significant differences in 
haemodynamic parameters in the population that developed GDM and hypertensive 
diseases of pregnancy demonstrate a role for the routine use of arteriography which 
could be performed at the booking appointment or the 1st trimester scan. It is an easy 
test to perform which only takes five minutes and is cheap following the initial purchase 
of the machine. Women at high risk of GDM could have early glucose tolerance tests 
performed and/or start performing capillary blood glucose monitoring early in order to 
prevent complications developing. 
 
The low false positive rate and high positive LR of 2nd trimester UAD for the prediction 
of stillbirth make it a useful screening test that should be routinely performed at the 
anomaly scan. It is easy, cheap and quick to perform. Screen positive pregnancies 
should then be offered serial surveillance of fetal wellbeing with growth scans, 
placental and fetal Doppler measurements. 
 
Section 8.4 Implications for Research 
 
The variable quality of published studies and the difference in the reporting of results 
leads to high heterogeneity and difficulty in performing meta-analysis with many studies 
having to be excluded due to the way that results have been reported. Future studies 
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need to adhere to standardised methodology to enable easier comparison and meta-
analysis, with study outcomes and population clearly differentiated. Future prediction 
models need to ensure the actual model is published allowing application and 
validation.   
 
The stillbirth review has highlighted the need for an individual patient data meta-
analysis to allow subgroup analysis based on timing of stillbirth and determine which 
UAD parameter and threshold value should be measured. 
 
The low number of cases of early PE in the primary study population identifies the need 
for further studies measuring maternal serum biomarkers in women with early onset 
disease. A retrospective case control study might be better at ensuring appropriate 
numbers of cases are included for analysis. The high number of women of South Asian 
ethnicity in our study population coupled with the high incidence of GDM and low 
incidence of PE demonstrates a possible role for investigating whether there is any 
protective effect from ethnicity and GDM. 
 
Further attempts to validate pre-existing PE models using other study group’s data 
from other populations should be performed to see if our results are replicated. Current 
models should be implemented in clinical practice and compared to existing 
management to assess whether the models improve patient care and outcomes.  
 
Future research on the effect of diet and lifestyle based metabolic risk modifying 
interventions on PE need to evaluate the effect of dietary interventions in women with 
pre-existing metabolic risk factors. Further research should also assess the effect of 
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interventions that modify metabolic risk factors such as lipid levels, blood pressure and 
glycaemic control on preeclampsia. Individual patient data meta-analysis of 
interventions of published trials will allow us to evaluate the differential effects of the 
intervention in various subgroups of women, and to undertake additional analysis by 




















Appendix 3.1: Details of the included studies in the biomarker review 
  
Paper Abdelaziz et al. 2012 
Methods Nested case controlled study 
Participants 2120 singleton pregnancies without a history hypertension, renal 
disease, autoimmune disease or obesity were recruited. After 
exclusion for loss to follow up and fetal loss <24 weeks there was 
1898 patients. There were 16 cases of PE<34 weeks and 60 cases 
of PE>34 weeks.  
Interventions Endoglin levels at 11-14 weeks  
Outcomes Gestational hypertension, PE requiring delivery <34 weeks, PE 
requiring delivery >34 weeks  
  
Paper Akolekar et al. 2009 
Methods Case controlled study 
Participants 8234 singleton pregnancies were recruited. There was 26 cases of 
early PE and 95 cases of late PE. These were matched with 208 
controls on the basis of length of sample storage.  
Interventions Inhibin-a levels at 11-13 weeks  
Outcomes Early PE, Late PE, gestational HTN  
  
Paper Akolekar et al. 2011 
Methods Case controlled study 
Participants 36,743 singleton pregnancies were recruited. After exclusion for 
incomplete data, fetal loss or major fetal anomaly there were 33,602 
patients. There were 112 cases of PE<34 weeks, 187 casesPE34-37 
weeks and 453 cases of PE>37 weeks. The 32,850 controls were 
pregnancies with no complications and normal outcome matched for 
duration of sample storage.  
Interventions activin-a, beta HCG, endoglin, Inhibin-a, PAPP-A, pentraxin3, PLGF, 
PP13, P-selectin levels at 11-13 weeks  
Outcomes PE <34 weeks,PE34-37 weeks, PE>37 weeks 
  
Paper Bauman et al. 2008 
Methods Case controlled study 
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Participants 46 cases of PE>34 weeks were identified in singleton pregnancies 
with no history of hypertensive disorders, renal disorders, 
immunological disease or HELLP. These were matched with 92 
controls on the basis of gestational age at blood sampling, maternal 
age, pre-pregnancy weight and duration of sample storage. 
Interventions Inhibin-a, PLGF, sEng, SFlt-1 levels at 11+2- 13+6 weeks  
Outcomes PE >34weeks 
  
Paper Bills et al. 2009 
Methods Cohort study 
Participants 50 pregnancies were recruited at antenatal clinic, a further 20 
pregnancies were recruited when a diagnosis of PE was made. 30 
pregnancies were excluded for PIH, idiopathic fetal growth 
restriction, IUD, loss to follow up, preterm labour or no available 1st 
trimester serum sample.  There were 25 cases of PE and 45 
normotensive pregnancies.  
Interventions VEGF levels in the 1st trimester 
Outcomes PE 
  
Paper Bosio et al. 2011 
Methods Case controlled study 
Participants 400 healthy primigravid women were recruited. The 20 cases of PE 
were matched with 26 controls on the basis of body mass index.  
Interventions P-selectin levels at 10-14 weeks 
Outcomes PE and gestational HTN 
  
Paper Cetin et al.  2009 
Methods Nested case controlled study 
Participants A cohort of singleton pregnancies without medical disorders or drug 
therapy were recruited. There were 16 cases of PE. The following 
two patients to be recruited after each case of PE or SGA acted as 
controls.  
Interventions Pentraxin3 levels at 11-14 weeks 
Outcomes PE and SGA requiring delivery <37 weeks 
  
Paper Chafetz et al. 2007 
Methods Nested case controlled study 
Participants Singleton pregnancies from the Massachusetts General Hospital 
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Obstetric Maternal Study cohort were recruited. Pregnancies were 
excluded if they were complicated by AIDS, hepatitis, fetal anomaly, 
fetal death, delivery <26 weeks, placenta praevia, placenta accreta 
or placental abruption. The 47 cases of PE were matched to 290 
controls on the basis of gestational age at time of sampling and 
storage time.  
Interventions PP13 levels at 9-12 weeks 
Outcomes PE, SGA, preterm labour 
  
Paper Chaiworapongsa et al. 2005 
Methods Case controlled study 
Participants Retrospective identification of 44 cases of PE. Patients with multiple 
pregnancies, major fetal anomaly or demise, active vaginal bleeding, 
serious medical illness, chronic hypertension, asthma and patients 
using non-steroidal anti-inflammatory drugs or anti-platelet agents 
were excluded. In the group of patients who had blood sampled 
between 7-16 weeks there were 4 cases of PE. The 37 controls were 
matched for gestational age at the time of sampling.    
Interventions sVEGFR-1 levels at 7-16 weeks 
Outcomes PE, PE<34wks  
  
Paper Dugoff et al, 2004 
Methods Prospective cohort study 
Participants 33,395 singleton pregnancies without fetal anomalies or insulin 
dependent diabetes mellitus were recruited. There were 764 cases 
of PE.  
Interventions Beta HCG, PAPP-A levels at 10+3-13+6 weeks 
Outcomes PE, Gestational hypertension, IUD, NND, preterm birth <37 weeks, 
preterm birth <32 weeks, placental abruption 
  
Paper El-Gharib et al, 2011 
Methods Prospective cohort study 
Participants 327 singleton pregnancies without hypertensive disorders, infection, 
diabetes mellitus or renal disease were recruited. 24 were lost to 
follow up leaving 303 patients. There were 26 cases of PE.  
Interventions Inhibin-A levels at 10-12 weeks 
Outcomes PE 
  
Paper El-Sherbiny et al. 2012 
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Methods Case controlled study 
Participants Pregnancies not complicated by essential hypertension, diabetes 
mellitus, recurrent pregnancy loss, hepatic disease, renal disease 
,severe infections, administration of antioxidants or smoking were 
recruited. 50 cases of PE were matched to 50 controls on the basis 
of gestational age.  
Interventions PP13 levels at 9-13 weeks 
Outcomes PE 
  
Paper Goetzinger et al. 2010 
Methods Retrospective cohort study 
Participants 4,035 singleton pregnancies were recruited, after exclusion for 
incomplete data and aneuploidy there were 3716 patients. There 
were 293 cases of PE.   
Interventions beta HCG and PAPP-A levels at 11-13 weeks  
Outcomes PE 
  
Paper Lynch et al, 2010 
Methods Prospective cohort study 
Participants 668 singleton pregnancies were recruited. Women were excluded if 
they had a repeat delivery within study period, PIH or IUD. There 
were 31 cases of PE.  
Interventions Bb, C3a, PlGF, SC5b-9,sEng, SFlt-1 levels at 10-15 weeks 
Outcomes PE 
  
Paper Madazili et al. 2013 
Methods Case controlled study 
Participants 31 cases of PE and 30 controls were selected after exclusion for 
multi fetal pregnancies, obesity, medical complications, pre-labour 
rupture of membranes and chorioamnionitis.   
Interventions PlGF, metastin and chitotriosidase levels at 11-14 weeks  
Outcomes PE, SGA  
  
Paper Noori et al, 2010 
Methods Prospective cohort study 
Participants 159 women with singleton pregnancies were recruited during 1st 
trimester ultrasound scan and the obstetric medicine clinic. There 
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were 10 cases of PE<37 weeks and 11 cases of PE>37 weeks. 
Interventions PLGF, sENG, sFlt-1 levels at 10-17 weeks 
Outcomes PE <37weeks, PE>37weeks, gestational hypertension 
  
Paper Odibo et al. 2011 
Methods Prospective cohort study 
Participants 477 singleton pregnancies were recruited. After exclusion for fetal 
loss<20 weeks, loss to follow up and fetal anomaly there were 452 
patients. There were 42 cases of PE and of these 12 required 
delivery <34 weeks. 
Interventions PAPPA, PP13 and PAPPA/PP13 levels at 11-14 weeks 
Outcomes PE and PE<34 weeks  
  
Paper Poon et al. 2009 
Methods Prospective cohort study 
Participants 8,679 singleton pregnancies were recruited. After exclusion for 
incomplete data, unclear diagnosis, fetal abnormality, miscarriage or 
termination there were 8,051 patients. There were 32 cases of 
PE<34 weeks and 124 after 34 wks.  
Interventions PAPP-A at 11+0-13+6 weeks  
Outcomes PE <34/40,PE>34/40 
  
Paper Radoi et al. 2009 
Methods Prospective cohort study 
Participants 484 pregnancies were recruited. After exclusion for multiple 
pregnancy, missing values for birth weight or perinatal outcome, 
gestational age at delivery outside range of 24-43 weeks, abnormal 
or missing karyotype there were 456 pregnancies. There were 19 
cases of PE. 
Interventions beta HCG and PAPP-A levels at 10-13+6 weeks  
Outcomes PE, birth weight <5th centile, preterm delivery and stillbirth 
  
Paper Rana et al. 2007.  
Methods Nested case controlled study 
Participants Singleton pregnancies without fetal anomalies were selected from 
the Massachusetts General Hospital Obstetric Maternal Study 
cohort. 39 cases of PE were matched with 147 controls on the basis 
of age and body mass index. 
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Interventions sEng and sFLT-1 levels at 11-13 weeks.  
Outcomes PE 
  
Paper Saloman et al. 2003.  
Methods Nested case controlled study 
Participants 4,870 singleton pregnancies were recruited. Patients were excluded 
in the presence of fetal abnormalities, glucose intolerance or 
gestational diabetes identified in the 2nd trimester. 30 cases of 
severe PE were matched to 60 controls on the basis of timing of 
sampling.  
Interventions Inhibin A and leptin levels at 7-13 weeks  
Outcomes Severe PE 
  
Paper Saruhan et al. 2011 
Methods Retrospective cohort study  
Participants 663 pregnancies were recruited. After exclusion for incomplete data, 
multiple pregnancy, fetal anomaly or the pregnancy resulting in 
miscarriage there were 318 pregnancies including 4 cases of PE.   
Interventions PAPP-A levels at 11-14 weeks 
Outcomes PE, SGA, preterm delivery, gestational HTN, gestational diabetes 
mellitus 
  
Paper Schneuer et al. 2012.  
Methods Prospective cohort study 
Participants 2,989 patients were recruited. After exclusion if sampling took place 
<10 or >14 weeks, termination of pregnancy, multi-fetal pregnancy or 
a major congenital anomaly there were 2,784 pregnancies including 
71 cases of PE and 4 cases of PE<34 weeks.  
Interventions PP13 levels at 10-14 weeks  
Outcomes PE,PE<34 weeks, SGA 
  
Paper Sebire et al. 2000 
Methods Prospective cohort study  
Participants 876 singleton pregnancies were recruited. After exclusion for 
incomplete data and chromosomally abnormal pregnancies there 
were 759 pregnancies including 9 cases of PE. 
Interventions Inhibin A and beta HCG levels at 10-14 weeks  
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Outcomes PE, SGA 
  
Paper Spencer et al. 2005 
Methods Case controlled  study 
Participants 64 cases of PE were matched to 3,999 controls. Patients were 
excluded if there was a multiple pregnancy or a fetal anomaly was 
identified.  
Interventions beta HCG and PAPP-A levels at 11-13+6 weeks  
Outcomes PE, preterm delivery, SGA 
  
Paper Thadhani et al. 2004 
Methods Prospective nested case control study 
Participants Pregnancies without diabetes, thyroid, liver or renal disease were 
selected from the Massachusetts General Hospital Obstetrical 
Maternal Study cohort. 40 cases of PE were matched with 80 
controls on basis of timing of sampling and gestational age at 
delivery.  
Interventions PlGF and sFlt1 levels <12 weeks 
Outcomes PE, SGA, gestational HTN  
  
Paper Vatten et al, 2007 
Methods Nested case control study  
Participants Cohort of 29,948 women from a prospective study of toxoplasma 
gondii infection in pregnancy. Patients were excluded if there was a 
multiple pregnancy or insufficient serum for sampling.  111 cases of 
preterm PE and 143 term PE were matched with 273 randomly 
selected controls in the PlGF group. 110 cases of preterm PE and 
144 cases of  term PE were matched with 276 randomly selected 
controls in the sflt-1 group.   
Interventions PlGF and sFlt-1 levels 4-12 weeks 
Outcomes PE <37 weeks, PE>37 weeks  
  
Paper Wortelboer et al. 2010 
Methods Case controlled study 
Participants 88 cases of early PE were matched with 480 controls on the basis of 
gestational age at sample date and duration of sample storage.  
Interventions PP13, PlGF, ADAM-12, PAPP-A, beta HCG levels at 8-13+6 weeks  




Paper Yaron et al. 2002 
Methods Prospective cohort study 
Participants 1772 patients were recruited. After exclusion for incomplete data, 
chromosomal abnormalities, and termination of pregnancy for fetal 
anomaly there were 1622 patients including 27 cases of PE.  
Interventions PAPP-A levels at 10-13 weeks  
Outcomes preterm labour, SGA, gestational hypertension, PE, intrauterine fetal 
death, oligohydramnios, miscarriage and placental abruption.  
  
Paper Zhong et al. 2011 
Methods Case controlled study  
Participants 4000 singleton pregnancies were recruited. After exclusion for 
incomplete data there were 3475 pregnancies including 278 cases of 
PE.  
Interventions beta HCG and PAPP-A levels at 11-13+6 weeks  














Appendix 3.2: Quality assessment of included studies in the biomarker review 












































































































































Bills 2009 −   − 2 Medium - 0 High  - - 1 Medium 
Dugoff 2004     4 Low  2 Low  - - 1 Medium 
El-Gharib 2011     4 Low - 0 High ★ - ★ 2 Medium 
Goetzinger 2010 ★ ★ − ★ 3 Medium - 0 High - - ★ 1 Medium 
Lynch 2010 ★ ★ ★ ★ 4 Low ★ 1 Medium ★ - ★ 2 Medium 
Noori 2010 ★ ★ − ★ 3 Medium  2 Low - ★ ★ 2 Medium 
Odibo  2011 ★ ★ ★ ★ 4 Low  1 Medium - - ★ 1 Medium 
Poon 2009  ★ − ★ 3 Medium  1 Medium ★ - ★ 2 Medium 
Radoi 2009 ★ ★ − ★ 3 Medium - 0 High - - ★ 1 Medium 
Saruhan 2011 ★ ★ − − 2 Medium - 2 High - - - 0 High 
Schneuer 2012 ★ ★ ★ ★ 4 Low - 2 High ★ - ★ 2 Medium 
Sebire 2000 ★ ★ − ★ 3 Medium - 2 High - - ★ 1 Medium 









Appendix 3.3 Funnel plots assessing publication bias 
PAPP-A and any onset PE
 




































PlGF and any onset preeclampsia 
 























PP13 and any onset preeclampsia 
 










PP13 and early onset preeclampsia 
 
 
SFLT-1 and any onset preeclampsia 
 
 









































Appendix 4.1: Data extraction form for stillbirth review 
Reviewer:           Paper No.:                  Language:                                           1st Author:    
 
1. Population –pregnant women                    yes / no   
                                                                                    
2. Test - Transabdominal UADS                   Transvaginal UADS 
 
3. Reference standard         Stillbirth 
 
 2x2 table construction possible                              yes / no   
         Select this diagnostic test study (1-3 inclusive) yes / no       if no reject & specify reason 
below   
……………………………………………………………………………………………………………………… ………..   
……………………………………………………………………………………………………………………… ………..            
Population:   
Study Design    Cohort / Cross-sectional / Case control / Other……………   
Data Collection   Prospective / Retrospective / Cannot tell / Other………….   
Patient Enrolment   Consecutive / Arbitrary / cannot tell / Other……………. 
 
Additional Description of Study Design   
 Blind comparison with reference standard             Yes               No                    Can‟t tell    
Defined sample of patients                                         Yes               No                    Can‟t tell   
 Narrow population spectrum                                     Yes               No                   Can‟t tell   
 Differential use of reference standard                     Yes                No                   Can‟t tell     
Baseline prevalence of the disease: .......................... (State figure if provided, otherwise circle 
below)   
High                                              Low                                        Not mentioned   
Please circle characteristic of sample population(s): [Assuming this is not a risk factor study]   
Associated medical problem                           Can‟t tell   
If sample classified, state the definition:   
......................................................................................................................................................    
Inclusion criteria stated                          Yes                      No               Description:   
......................................................................................................................................................    
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No. patients recruited    
A original population   n=……   
B Pre-enrolment exclusions n=……              (reasons eg pop 
characteristics)……………………………………   
C actually recruited (A-B)   n=……           
D post-enrolment exclusions n=…… (reasons eg missing data etc)…………………………………………   
E analysable data (C-D)  n=……    
   
Parity stated:                                     Yes                       No                                   not sure      
 
Intervention:   
 
Type of intervention („the test‟): …………………………………   
 
How many measurement(s):        Single           Multiple   
 
Gestation at which „the test‟ was applied: ............weeks or ............ trimester   
 
Method described:                       Yes                           No      
If there‟s  a cut off level, this must be stated for the test to be considered adequate:   Yes       
No   
Cut off level of the test: ……   
Test positive cases    n=……    
Test negative cases    n=……      
State fetal outcome:                                  …  
Blinding of test result   yes / no   
Completeness of Follow up (%)  >90 / 81-90 / <81  (FU% = E/C x 100% =…… %)   
Completeness of Follow up (%)   
Positive cases  % 
 Negative cases %  
Regarding the outcome(s):   
How was the result reported [ie the summary outcome measure(s)]: {please circle}  
Receiver Operator Curve (summary) ROC               LR (LR)   
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Sensitivity              Specificity                 Negative predictive value                  Positive predictive 
value   
Others (please state): ........................................................................................    





Outcome (stillbirth): (2x2 table)   
Population.................................................Outcome……………………………………….   
 
 Outcome present Outcome absent Total 
Positive    
Negative    













Appendix 4.2: Details of the included studies in the stillbirth review 
Paper Madazali et al. 2014 
Methods Cohort study 
Participants 65 pregnancies in women with SLE were examined between 2002-2011 
Interventions Average UAD SD ratio>2.6 and bilateral notching 
Outcomes Stillbirth, fetal growth restriction, PE, preterm birth 
  
Paper Jamal et al. 2013 
Methods Cohort study 
Participants 435 consecutive singleton pregnancies attending for prenatal care at 18-24 
weeks in 3 university hospitals. Inclusion criteria were signet pregnancies 
with normal foetuses, not taking aspirin, heparin, metformin or anti-
hypertensive drugs 
Interventions UAD mean PI >95th percentile and/or bilateral notches 
Outcomes Stillbirth, PE, fetal growth restriction, preterm delivery, placental abruption 
  
Paper Poon et al 2013 
Methods Cohort study 
Participants 65, 819 singleton pregnancies. 30, 566 pregnancies were examined between 
1999 and 2002 at 7 hospitals that were collaborating in a trial using low 
dose aspirin for the prevention of PE. In this group gestational age was 
calculated by measurement of head circumference. 35, 253 pregnancies 
were examined between 2006 and 2011 at 3 hospitals , gestational age was 
calculated by measuring the crown rump length in this group. 306 women 
had stillbirths 
Interventions Uterine artery PI MoM >90th centile at 20-24 weeks gestation 
Outcomes Antepartum stillbirth, intrapartum stillbirth, placental abruption, SGA, PE 
  
Paper Singh et al. 2012 
Methods Cohort study 
Participants Nulliparous women or women with obstetric history of placental syndromes 
(fetal growth restriction, PE, or stillbirth) underwent second-trimester UAD 
assessment at 19-23 weeks’ gestation. Outcomes were available for a final 
cohort of 15,796 women included 134 antepartum stillbirths. 





Paper Iacovella et al. 2012 
Methods Cohort study 
Participants 9859 unselected women with singleton pregnancies attending for a routine 
11-14 week ultrasound scan. 
Interventions UAD RI >90th centile 
Outcomes Stillbirth. 
  
Paper Filippi et al. 2011 
Methods Cohort study 
Participants 273 women with one or more extreme levels of feto-placental proteins 
(PAPP-A ≤0.28 MoM, inhibin A ≥3.0 MoM, 2nd trimester β-hCG ≥4.0 MoM, 
AFP ≥2.5 MoM and 
estriol ≤0.5 MoM) were offered UAD at 24-26 weeks. UAD examination was 
performed in 159 women. Among these women there were two cases of 
stillbirth. 
Interventions Uterine artery notches or mean uterine artery pulsatile index  1.45 at 24-
26 weeks. 
Outcomes SGA, low birthweight, preterm delivery, late miscarriage, stillbirth, placental 
abruption and gestational hypertension. 
  
Paper Proctor et al. 2009 
Methods Cohort study 
Participants 90 women with singleton, chromosomally normal pregnancies and very low 
levels of PAPP-A (≤0.30 MoM) at 11–13 weeks’ gestation. 15 stillbirths were 
observed in the cohort.  
Interventions Placental ultrasound assessment was performed at 18-24 weeks. The 
ultrasound examination included measurement of placental size and 
assessment of the UAD mean pulsatility index. 
Outcomes IUGR, preterm delivery before 32 weeks, intra-uterine death. 
  
Paper Fratelli et al. 2008 
Methods Prospective cohort study 
Participants 76 women with singleton pregnancies between 11-14 weeks gestation 
classified as high risk due to a previous history of HELLP, eclampsia, early 
onset PE, chronic disease e.g. chronic hypertension, inherited 
thrombophilia, autoimmune disease, renal disease and a history of IUGR, 
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stillbirth or placental abruption in a previous pregnancy 
Interventions Bilateral notches or mean UAD RI >0.8 
Outcomes IUGR, PE, intra-uterine death and placental abruption 
  
Paper Schwarze et al. 2005 
Methods Cohort study 
Participants 346 women with singleton “low risk” pregnancies between 19 and 26 
weeks’ gestation. Women who fulfilled the following criteria were excluded 
from the study: essential hypertension, diabetes mellitus, autoimmune 
disorders, history of PE, IUGR, IUD and/or placental abruption in previous 
pregnancies. Two IUDs occurred in the study group. 
Interventions Uterine artery notches or mean uterine artery resistance index at 19-26 
weeks. 
Outcomes PE, intra-uterine growth restriction, intra-uterine death and placental 
abruption. 
  
Paper Axt-Fliedner et al. 2005 
Methods Cohort study 
Participants 52 women with singleton “risk” pregnancies defined by the presence of 
essential hypertension or an obstetric history of: PE, intrauterine growth 
retardation, IUD, placental abruption. Four IUDs occurred in the study 
group. 
Interventions Uterine artery notches or mean uterine artery resistance index at 19-26 
weeks. 
Outcomes PE, intra-uterine growth restriction, intra-uterine death and placental 
abruption. 
  
Paper Albaiges et al. 2000 
Methods Cross-sectional study 
Participants 1941 consecutive women with singleton pregnancies at 22 to 25 weeks’ 
gestation. Complete demographic and outcome data were available for 
1757 women. Six women had an IUD. 
Interventions Bilateral uterine artery notches or mean uterine artery pulsatile index of 
1.45 or higher at 22-25 weeks. 
Outcomes PE, birth weight, fetal death and placental abruption. 
  
Paper Coleman et al, 2000 
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Methods Prospective cohort study 
Participants 116 pregnancies in women who had high risk for PE due to one of the 
following conditions: essential hypertension, secondary hypertension, pre-
existing renal disease, systemic lupus erythematosus, antiphospholipid 
syndrome, previous recurrent PE, previous early-onset PE requiring delivery 
at ≤ 32 weeks, previous placental abruption. There were two IUDs in the 
cohort. 
Interventions Uterine artery notches or any resistance index > 0.58 or ≥ 0.7 at 22-24 
weeks. 
Outcomes PE, SGA, intra-uterine death, placental abruption. 
  
Paper Bewley et al. 1991 
Methods Cross-sectional study 
Participants 977 women at 16-24 weeks of gestation. Statistical analysis was performed 
in 925 women, the remainder being excluded for a variety of reasons. 
Twelve women had an IUD (nine at > 24 weeks). 
Interventions Average resistance index from four sites (left and right uterine and arcuate 
arteries) at 16-24 weeks. 
Outcomes IUD, birthweight, pregnancy-induced hypertension, antepartum 
haemorrhage. 
  
Paper Steel et al. 1990 
Methods Cohort study 
Participants 1014 nulliparous women <25 weeks gestation 
Interventions Uterine artery >RI.0.58 
Outcomes Stillbirth, PIH, PE, SGA 
  
Paper Fleischer et al. 1986 
Methods Cohort study 
Participants 71 women with hypertensive disorders in pregnancy (chronic hypertension, 
PE, chronic hypertension with superimposed PE) including 17 cases of 
stillbirth.  
Interventions Uterine artery notches or systolic/diastolic ratio >2.6 in the third trimester. 





Appendix 5.1: Univariate and multivariate odds ratios in prediction of each 





To calculate AIX-5075/(10^(2.12215+0.0036873×(age-30) -0.189846×height in meters 
– 0.000464×weight in kg + 0.0159757 if ethnicity=2 +0.0209559 if ethnicity=5 – 
0.0085961 if parity=1)) 
------------------------------------------------------------------------------- 
     laix5075 |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
          age |   .0036873   .0003851     9.57   0.000     .0029315     .004443 
 heightmeters |   -.189846   .0310765    -6.11   0.000    -.2508264   -.1288656 
       weight |   -.000464   .0001542    -3.01   0.003    -.0007666   -.0001614 
_Iethnicity_2 |   .0159757   .0046511     3.43   0.001      .006849    .0251025 
_Iethnicity_5 |   .0209559   .0095659     2.19   0.029      .002185    .0397267 
   _Iparity_1 |  -.0085961   .0039958    -2.15   0.032     -.016437   -.0007553 
















To calculate PWV MoMs: PWV/(10^((0.5984581 +0.0032231×(age-30)+ 0.0120506 if 
parity=1 + 0.00711×weight in kg + 0.0021199×MAP)) 
------------------------------------------------------------------------------ 
        lpwv |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         age |   .0032231   .0004008     8.04   0.000     .0024365    .0040096 
  _Iparity_1 |   .0120506   .0041692     2.89   0.004     .0038696    .0202316 
      weight |    .000711   .0001567     4.54   0.000     .0004034    .0010185 
         map |   .0021199   .0002175     9.75   0.000     .0016931    .0025466 
       _cons |   .5984581   .0195684    30.58   0.000     .5600598    .6368565 
------------------------------------------------------------------------------ 
 
To calculate SBPAO MoMs: SBPAO/(10^(1.987581+.0012261×(age-30) -0.0133686 if 




       lsbpao |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
          age |   .0012261   .0002847     4.31   0.000     .0006673    .0017848 
   _Iparity_1 |  -.0133686    .002942    -4.54   0.000    -.0191415   -.0075957 
       weight |    .000805    .000108     7.45   0.000     .0005931     .001017 
_Iethnicity_2 |   .0104739   .0031164     3.36   0.001     .0043588    .0165891 
_Iethnicity_5 |   .0197938    .007065     2.80   0.005     .0059303    .0336573 





































 PAPP-A  MoM : log linear AxB GA(days)  
free beta hCG: log quadratic AxB GA (days)xC (GAxGA) 
PlGF MoM = PlGF/(10^(0.3715965 +0.0168119*gestational age – 0.0023571*weight + 
0.127651 if smoke + 0.0479465 if Black + 0.1090515 if Mixed/other)) 
 
AFP MoM= AFP/(10^(-0.1200957+0.017231*gestational age – 0.0042275*weight + 0.0837082 




        lplgf |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
           ga |   .0130329   .0015017     8.68   0.000     .0100863    .0159796 
       weight |  -.0015144   .0005067    -2.99   0.003    -.0025086   -.0005202 
   _Ismoker_1 |   .1281146   .0350467     3.66   0.000     .0593442    .1968851 
_Iethnicity_2 |   .0937059   .0150135     6.24   0.000     .0642456    .1231663 
_Iethnicity_3 |   .0667281   .0226997     2.94   0.003     .0221856    .1112706 
_Iethnicity_4 |   .1622237   .0226803     7.15   0.000     .1177192    .2067283 























         lafp |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
           ga |   .0188195   .0017715    10.62   0.000     .0153433    .0222956 
       weight |  -.0028302   .0005904    -4.79   0.000    -.0039887   -.0016717 
_Iethnicity_4 |   .0808776   .0262722     3.08   0.002      .029325    .1324303 
_Iethnicity_2 |  -.0472127   .0167032    -2.83   0.005    -.0799885   -.0144369 





          map |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
_Iethnicity_3 |      -2.42    1.10586    -2.19   0.029    -4.589978    -.250022 
       weight |        .14   .0253828     5.52   0.000     .0901926    .1898074 





      meanpi |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         crl |  -.0047717   .0020781    -2.30   0.022    -.0088494    -.000694 
heightmeters |  -.7249249   .2280844    -3.18   0.002    -1.172485   -.2773653 





Univariate and multivariate odds ratios in prediction of each outcome. ROC curves 
based on multivariate model 
PE 
  Univariate     Multivariate   
 




OR 95% CI 
p-
value 
Ethnicity (vs Caucasian)               
South Asian 0.62 (0.15 to 2.59) 0.509 
 
- 
 Oriental - 
 
- 
 Afro-Caribbean 4.61 (1.38 to 15.41) 0.013 
 




 Previous PE - 
 
- 
 FHx Mother 6.02 (0.73 to 49.45) 0.095 
 FHx Sister - 
 FHx Mother/sister 2.75 (0.35 to 21.78) 0.337 
 Hypertension 8.73 (1.03 to 73.96) 0.047 
 
- 
 Diabetes - 
 
- 
 Smoker 2.06 (0.26 to 16.20) 0.49 
 
- 
 Parity 0.95 (0.33 to 2.76) 0.927 
 
- 
 Conception 3.88 (0.48 to 31.14) 0.201 
 
- 
 Systolic BP 1.05 (1.02 to 1.09) 0.001 
 
- 
 Diastolic BP 1.08 (1.03 to 1.13) 0.001 
 
- 
 Height (m) 0.94 (0.00 to 1233.71) 0.987 
 
- 
 Weight (kg) 1.01 (0.98 to 1.05) 0.415 
 
- 
 log10 AIX-75 MoM 8297.71 (3.46 to  2.0e+07) 0.023 
 
- 
 log10 PWV MoM 0.77 (0.00 to 7337.85) 0.956 
 
- 
 log10 SBPAO MoM 5.40E+07 (3181.71 to  9.3e+11) <0.001 
 
- 
 MAP MoM 693.63 (15.58 to 30877.72) 0.001 
 
491.46 (10.28 to 23487.85) 0.002 
Mean PI MoM 3.69 (0.86 to 15.81) 0.078 
 
- 
 log10 AFP MoM 0.65 (0.05 to 8.90) 0.746 
 
- 
 log10 free β-hCG MoM 0.55 (0.07 to 4.42) 0.575 
 
- 
 log10 PAPP-A MoM 0.54 (0.06 to 5.11) 0.587 
 
- 




Probability=exp(-11.23373+6.197378* MAP MoM)/(1+exp(-11.23373+6.197378*MAP MoM))  
OR Probability=exp(-11.23373+6.197378* MAP MoM +1.827809)/(1+exp(-
11.23373+6.197378* MAP MoM +1.827809)) if ethnicity group=4 
 
 
95% CI for AUC 0.6928-0.9340 
PIH 
  Univariate     Multivariate   
 




OR 95% CI 
p-
value 
Ethnicity (vs Caucasian)               
South Asian 0.77 (0.26 to 2.24) 0.631 
 
- 
 Oriental 1.37 (0.36 to 5.23) 0.651 
 
- 
 Afro-Caribbean 2.36 (0.76 to 7.37) 0.139 
 
- 
 Other/Mixed/Unknown 1.13 (0.14 to 9.26) 0.909 
 
- 
















0% 25% 50% 75% 100%
False-positive rate
Area under ROC curve = 0.8134
181 
 
FHx Mother 3.52 (0.44 to 28.14) 0.235 
 
- 
 FHx Sister - 
 
- 
 FHx Mother/sister 1.61 (0.21 to 12.38) 0.646 
 
- 
 Hypertension 5.11 (0.62 to 42.10) 0.129 
 
- 
 Diabetes - 
 
- 
 Smoker 1.21 (0.16 to 9.21) 0.855 
 
- 
 Parity 0.44 (0.17 to 1.13) 0.087 
 
- 
 Conception - 
 
- 
 Systolic BP 1.05 (1.02 to 1.08) <0.001 
 
- 
 Diastolic BP 1.09 (1.05 to 1.13) <0.001 
 
- 
 Height (m) 78.88 (0.32 to 19316.29) 0.120 
 
- 
 Weight (kg) 1.04 (1.01 to 1.06) 0.001 
 
1.04 (1.01 to 1.06) 0.002 
log10 AIX-75 MoM 1696.54 (2.17 to  1.3e+06) 0.029 
 
- 
 log10 PWV MoM 28.66 (0.05 to 18164.26) 0.308 
 
- 
 log10 SBPAO MoM 4.90E+05 (153.27 to  1.5e+09) 0.001 
 
- 
 MAP MoM 633.52 (29.12 to 13781.10) <0.001 
 
457.66 (21.71 to 9647.42) <0.001 
Mean PI MoM 1.01 (0.25 to 3.99) 0.992 
 
- 
 log10 AFP MoM 1.1 (0.14 to 8.43) 0.926 
 
- 
 log10 free β-hCG MoM 0.42 (0.07 to 2.35) 0.323 
 
- 
 log10 PAPP-A MoM 0.66 (0.10 to 4.27) 0.665 
 
- 











        mmap |    6.12613   1.555292     3.94   0.000     
3.077813    9.174446 
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      weight |   .0367303   .0119601     3.07   0.002     
.0132889    .0601716 
       _cons |  -12.68619   1.904232    -6.66   0.000    -









  Univariate     Multivariate   
 
OR 95% CI 
p-
value   OR 95% CI 
p-
value 
Ethnicity (vs Caucasian) 
















0% 25% 50% 75% 100%
False-positive rate
Area under ROC curve = 0.7597
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Oriental 3.76 (1.19 to 11.90) 0.024 
 
- 
 Afro-Caribbean 1.86 (0.46 to 7.57) 0.385 
 
- 
 Other/Mixed/Unknown 1.52 (0.18 to 12.88) 0.703 
 
3.77 (2.03 to 6.98) <0.001 
Previous PE - 
 
- 
 FHx Mother - 
 
- 
 FHx Sister - 
 
- 
 FHx Mother/sister - 
 
- 
 Hypertension - 
 
- 
 Diabetes - 
 
- 
 Smoker 1.16 (0.27 to 4.96) 0.842 
 
- 
 Parity 1.4 (0.78 to 2.50) 0.254 
 
- 
 Conception 1.04 (0.14 to 7.90) 0.971 
 
- 
 Systolic BP 1.02 (1.00 to 1.04) 0.091 
 
- 
 Diastolic BP 1.03 (1.00 to 1.06) 0.036 
 
- 
 Heignt (m) 0 (0.00 to 0.10) 0.002 
 
- 
 Weight (kg) 1 (0.98 to 1.03) 0.705 
 
- 
 log10 AIX-75 MoM 228.73 (1.38 to 37818.54) 0.037 
 
- 
 log10 PWV MoM 38.36 (0.41 to 3612.02) 0.116 
 
- 
 log10 SBPAO MoM 888.85 (1.98 to  4.0e+05) 0.029 
 
- 
 MAP MoM 16.58 (1.39 to 197.33) 0.026 
 
21.78 (1.76 to  270.24) 0.016 
Mean PI MoM 0.72 (0.26 to 1.93) 0.510 
 
- 
 log10 AFP MoM 0.83 (0.20 to 3.48) 0.801 
 
- 
 log10 free β-hCG MoM 0.28 (0.07 to 1.07) 0.062 
 
- 
 log10 PAPP-A MoM 1.88 (0.44 to 8.15) 0.396 
 
- 









_Iethnicity_5 |   1.326385   .3147693     4.21   0.000     
.7094489    1.943322 
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         mmap |   3.080947   1.284895     2.40   0.016     
.5625987    5.599296 
        _cons |  -6.861906   1.369835    -5.01   0.000    -




95% CI for AUC 0.6424-0.7809 
IUD 
  Univariate     Multivariate   
 
OR 95% CI 
p-
value   OR 95% CI 
p-
value 
Ethnicity (vs Caucasian) 
 South Asian 2.07 (0.19 to 22.90)     0.554 
 
- 
 Oriental - 
 
- 
 Afro-Caribbean - 
 
- 
 Other/Mixed/Unknown - 
 
- 
 Previous PE - 
 
- 
 FHx Mother - 
 
- 
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FHx Mother/sister - 
 
- 
 Hypertension - 
 
- 
 Diabetes - 
 
- 
 Smoker 13.57 (1.20 to 153.00) 0.035 
 
17.88 (1.43 to 224.28) 0.025 
Parity 2.55 (0.23 to 28.16) 0.446 
 
- 
 Conception - 
 
- 
 Systolic BP 1.04 (0.97 to 1.12) 0.248 
 
- 
 Diastolic BP 1.08 (0.98 to 1.18) 0.104 
 
- 
 Heignt (m) 174.81 (0.00 to  5.5e+08) 0.499 
 
- 
 Weight (kg) 1.02 (0.96 to 1.09) 0.463 
 
- 
 log10 AIX-75 MoM 0 (0.00 to  5.8e+06) 0.473 
 
- 
 log10 PWV MoM 2251.22 (0.00 to  1.1e+09) 0.248 
 
- 
 log10 SBPAO MoM 2065.3 (0.00 to  2.4e+13) 0.519 
 
- 
 MAP MoM 425.57 (0.15 to  1.2e+06) 0.137 
 
- 
 Mean PI MoM 1.81 (0.05 to 60.35) 0.739 
 
- 
 log10 AFP MoM 1197.4 (4.41 to  3.3e+05) 0.013 
 
- 
 log10 free β-hCG MoM 0.04 (0.00 to 15.53) 0.292 
 
- 
 log10 PAPP-A MoM 6.7 (0.01 to 4021.93) 0.56 
 
- 











      lmplgf |  -5.262748   2.187921    -2.41   0.016    -
9.550995   -.9745017 
      smoker |   2.883772   1.290401     2.23   0.025     
.3546324    5.412911 
       _cons |  -6.843647   .9315489    -7.35   0.000    -













  Univariate     Multivariate   
 
OR 95% CI 
p-
value   OR 95% CI 
p-
value 
Ethnicity (vs Caucasian) 
 South Asian 1.75 (0.94 to 3.26) 0.076 
 
1.83 (1.01 to 3.33) 0.047 
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Afro-Caribbean 2.03 (0.88 to 4.70) 0.097 
 
- 
 Other/Mixed/Unknown 2.87 (1.00 to 8.19) 0.049 
 
3.1 (1.04 to 9.28) 0.043 
Previous PE - 
 
- 
 FHx Mother 1.18 (0.15 to 9.17) 0.874 
 
- 
 FHx Sister 1.1 (0.14 to 8.46) 0.931 
 
- 
 FHx Mother/sister 1.14 (0.26 to 4.90) 0.862 
 
- 
 Hypertension 6.84 (1.72 to 27.09) 0.006 
 
- 
 Diabetes 1.54 (0.19 to 12.22) 0.683 
 
- 
 Smoker 3.06 (1.23 to 7.62) 0.016 
 
3.36 (1.23 to 9.15) 0.018 
Parity 1.47 (0.89 to 2.45) 0.134 
 
- 
 Conception 1.63 (0.37 to 7.16) 0.517 
 
- 
 Systolic BP 1.01 (0.99 to 1.03) 0.242 
 
- 
 Diastolic BP 0.99 (0.97 to 1.02) 0.601 
 
- 
 Heignt (m) 0.79 (0.03 to 24.89) 0.895 
 
- 
 Weight (kg) 1.01 (0.99 to 1.03) 0.238 
 
- 
 log10 AIX-75 MoM 12.42 (0.11 to 1463.16) 0.300 
 
- 
 log10 PWV MoM 0.43 (0.01 to 36.10) 0.708 
 
- 
 log10 SBPAO MoM 13.76 (0.05 to 3607.49) 0.356 
 
1.50E+08 (1246.77 to  1.8e+13) 0.002 
MAP MoM 0.49 (0.04 to 5.54) 0.567 
 
0.00 (0.00 to 0.17) 0.008 
Mean PI MoM 2.52 (1.16 to 5.46) 0.019 
 
- 
 log10 AFP MoM 4.02 (1.17 to 13.80) 0.027 
 
- 
 log10 free β-hCG MoM 1.7 (0.61 to 4.76) 0.313 
 
3.55 (1.20 to 10.52) 0.022 
log10 PAPP-A MoM 0.13 (0.04 to 0.41) <0.001 
 
0.26 (0.07 to 0.90) 0.034 








  ethnicity2 |   .6061936   .3050174     1.99   0.047     
.0083705    1.204017 
  ethnicity5 |   1.131371   .5592371     2.02   0.043     
.0352868    2.227456 
     lmsbpao |   18.83594   5.973393     3.15   0.002     
7.128309    30.54358 
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        mmap |  -6.720448   2.513498    -2.67   0.008    -
11.64681   -1.794083 
      lmplgf |  -2.886241   .7754534    -3.72   0.000    -
4.406102    -1.36638 
     lmfbeta |   1.266588   .5543333     2.28   0.022     
.1801152    2.353062 
     lmpappa |  -1.354924   .6383569    -2.12   0.034    -
2.606081   -.1037678 
      smoker |   1.210795   .5115088     2.37   0.018     
.2082565    2.213334 
       _cons |   3.303709   2.484663     1.33   0.184    -
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  Univariate     Multivariate   
 
OR 95% CI 
p-
value   OR 95% CI 
p-
value 
Ethnicity (vs Caucasian) 
 South Asian 1.32 (0.84 to 2.09) 0.234 
 
- 
 Oriental 1.30 (0.67 to 2.55) 0.438 
 
- 
 Afro-Caribbean 1.57 (0.83 to 2.98) 0.169 
 
- 
 Other/Mixed/Unknown 1.84 (0.77 to 4.42) 0.172 
 
- 
 Previous PE - 
 
- 
 FHx Mother 2.17 (0.60 to 7.89) 0.24 
 
- 
 FHx Sister 1.21 (0.27 to 5.43) 0.803 
 
- 
 FHx Mother/sister 1.66 (0.62 to 4.44) 0.311 
 
- 
 Hypertension 5.38 (1.50 to 19.35) 0.01 
 
4.40 (1.16 to 16.78) 0.030 
Diabetes 1.76 (0.37 to 8.23) 0.475 
 
- 
 Smoker 1.20 (0.46 to 3.13) 0.713 
 
- 
 Parity 1.31 (0.89 to 1.92) 0.169 
 
- 
 Conception 0.82 (0.19 to 3.58) 0.795 
 
- 
 Systolic BP 1.00 (0.99 to 1.02) 0.686 
 
- 
 Diastolic BP 0.99 (0.97 to 1.01) 0.452 
 
- 
 Heignt (m) 0.54 (0.04 to 7.44) 0.648 
 
- 
 Weight (kg) 1.01 (1.00 to 1.03) 0.082 
 
- 
 log10 AIX-75 MoM 3.46 (0.08 to 141.89) 0.512 
 
- 
 log10 PWV MoM 1.65 (0.06 to 43.99) 0.765 
 
- 
 log10 SBPAO MoM 1.06 (0.01 to 80.11) 0.98 
 
- 
 MAP MoM 0.52 (0.08 to 3.20) 0.477 
 
- 
 Mean PI MoM 1.69 (0.92 to 3.13) 0.093 
 
- 
 log10 AFP MoM 1.41 (0.55 to 3.62) 0.474 
 
- 
 log10 free β-hCG MoM 1.08 (0.49 to 2.37) 0.856 
 
- 
 log10 PAPP-A MoM 0.21 (0.09 to 0.50) <0.001 
 
0.38 (0.15 to 0.97) 0.042 











      lmplgf |  -1.906537   .5976591    -3.19   0.001    -
3.077927   -.7351466 
     lmpappa |  -.9722679   .4782688    -2.03   0.042    -
1.909657   -.0348783 
hypertension |   1.482275   .6825878     2.17   0.030     
.1444273    2.820122 
       _cons |  -2.206498   .1142247   -19.32   0.000    -
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Appendix 5.2: Summary table of results for all outcomes
Outcome PET PIH SGA<10th 
centile 
SGA<5th centile Stillbirth GDM 
FPR 5 10 15 20 5 10 15 20 5 10 15 20 5 10 15 20 5 10 15 20 5 10 15 20 
Sensitivity 28 50 72 72 30 40 48 72 27 30 30 40 27 50 57 57 62 65 67 100 17 25 45 55 
AUC 0.8134 0.7597 0.6084 0.7304 0.9225 0.7116 




Appendix 5.3: Serial results for AFP and PlGF 
 
  AFP      PlGF     
Outcom
e OR 95% CI p-value  OR 95% CI p-value 
PE 1.62 
(0.00 to 
7518.95) 0.911 0.72 (0.00 to 123.13) 0.900 
PIH 0.74 (0.00 to 128.16) 0.91 0.00 (0.00 to 1.07) 0.053 
GDM 1.76 (0.01 to 474.14) 0.843 0.86 (0.01 to 72.52) 0.947 
SGA5 0.95 (0.00 to 509.06) 0.988 0.00 (0.00 to 0.56) 0.037 
SGA10 0.12 
(0.00 to  
8.7e+14) 0.909  0.00 (0.00 to 0.25) 0.014 
 
Appendix 5.4: Power calculation 
When comparing two screening tests for prediction of preeclampsia in the same group 
of women, comparison is not made between the number of preeclamptics correctly 
predicted by the two tests, but instead between the number correctly predicted by test 
1, but not by test 2, and the number detected by test 2 and not by test 1. To obtain 70 
cases of PE amongst pregnant women in whom the prevalence of the disease is 5%, 
1250 women would have to be recruited.  Assuming the sensitivity of a test based on 
UADs alone in the first trimester is 60%, it would be expected that 42 of the 70 cases 
would be detected by Test 1.  A test based on UADs and biochemistry would be 
considered superior if the sensitivity could be increased to at least 80%, while retaining 
the specificity of Test 1 (which can be fixed in the analysis).  Therefore Test 2 is 
considered superior if it can detect at least 56 of the 70 cases.  A table comparing the 







  Test  2  
  Positive Negative  
Test 
1 
Positive a b 42 
 Negative c d 28 
  56 14 70 
 
It is necessary to estimate the numbers in the body of the table (a, b, c, and d) to 
assess formally whether Test 2 is superior to Test 1.  Statistical significance is 
assessed by comparing b and c.  It seems reasonable to suppose that around 15% of 
cases would not be detected by either test (when the sensitivity of Test 2 is 80%), 
giving d=12 (then a=40, b=2 and c=16).  With these figures, the study has 80% power 











Appendix 6.1: AUC-ROC comparison between validation’s cohorts 
 



















Akolekar, 2008 Early 30 (3.1%) 961 0.714 
(0.618; 
0.810) 




Akolekar, 2008 Late 34 (3.3%) 1,038 0.744 
(0.657; 
0.832) 








DiLorenzo, 2012 Late 38 (3.3%) 1,143 0.716 
(0.636; 
0.796) 




Goetzinger, 2010 Overall 38 (3.3%) 1,143 0.627 
(0.535; 






Plasencia, 2008 Early 38 (3.3%) 1,136 0.703 
(0.619; 
0.787) 




Plasencia, 2008 Late 38 (3.4%) 1,130 0.625 
(0.538; 
0.713) 




Poon, 2008 Overall 38 (3.3%) 1,137 0.687 
(0.606; 
0.768) 




Poon, 2009a Early 30 (3.0%) 994 0.761 
(0.671; 
0.850) 




Poon, 2009a Late 30 (3.0%) 994 0.679 
(0.581; 
0.776) 




Poon, 2009b Early 38 (3.4%) 1,130 0.831 
(0.764; 
0.898) 




Poon, 2009b Late 38 (3.4%) 1,125 0.816 
(0.753; 






Poon, 2009c Early 30 (3.1%) 958 0.828 
(0.758; 
0.898) 




Poon, 2009c Late 30 (3.1%) 958 0.788 
(0.712; 
0.865) 






Early 34 (3.3%) 1038 0.713 
(0.637; 
0.788) 






Late 34 (3.3%) 1038 0.667 
(0.572; 
0.763) 






Early 38 (3.4%) 1130 0.839 
(0.780; 
0.899) 






Late 30 (3.0%) 993 0.698 
(0.596; 
0.800) 






Early 38 (3.3%) 1143 0.735 
(0.657; 
0.812) 




Baschat,  Late 30 (3.0%) 1000 0.734 
(0.643; 
































Appendix 6.2 - Hosmer-Lemeshow calibration tables 
Study Risk group Women PE No PE Hosmer-Lemeshow P-Value 
Expected Observed Expected Observed 
Akolekar Early 1 472 0.1 2 471.9 470 <0.001 
2 472 0.7 5 471.3 467 
3 472 2.7 14 469.3 458 
4 472 40.5 23 431.5 449 
Akolekar Late 1 519 1.7 3 517.3 516 0.167 
2 519 4.4 7 514.6 512 
3 519 9 10 510.0 509 
4 519 33 28 486.0 491 
DiLorenzo Early 1 233 0.4 5 232.6 228 <0.001 
2 232 1 1 231.0 231 
3 232 2 4 230.0 228 
4 232 10.6 4 221.4 228 
DiLorenzo Late 1 550 10.3 3 539.7 547 0.001 
2 550 12.3 7 537.7 543 
3 546 13.6 18 532.4 528 
199 
 
4 540 15.7 24 524.3 516 
Goetzinger 2010 1 1145 14.6 16 1130.4 1129 0.342 
2 203 4.5 6      198.5        197 
3 623 19.8 15       603.2 608 
 4 215 13.1 15 201.9 200  
Plasencia Early 1 544 0.4 2 543.6 542 <0.001 
2 543 1.8 10 541.2 533 
3 544 5.6 15 538.4 529 
4 543 44.2 25 498.8 518 
Plasencia Late 1 542 2.4 3 539.6 539 <0.001 
2 542 5.3 14 536.7 528 
3 542 10.8 11 531.2 531 
4 542 33.5 24 508.5 518 
        
Poon 2008 1 545 2.7 3 542.3 542 0.467 
 2 545 7 7 538.0 538  
 3 545 11.6 15 533.4 530  
 4 545 30.7 27 514.3 518  
200 
 
Poon 2009a Early 1 481 0.5 1 480.5 480 0.001 
 2 481 1.9 6 479.1 475  
 3 481 5.4 9 475.6 472  
 4 481 36.2 28 444.8 453  
Poon 2009a Late 1 482 2.6 5 479.4 477 0.241 
 2 481 5.8 7 475.2 474  
 3 482 9.7 9 472.3 473  
 4 481 25.9 23 455.1 458  
Poon 2009b Early 1 542 0.2 1 541.8 541 0.023 
 2 542 1.2 3 540.8 539  
 3 542 4.5 6 537.5 536  
 4 542 46.2 42 495.8 500  
Poon 2009b Late 1 541 1.3 2 539.7 539 0.738 
 2 540 4 3 536.0 537  
 3 541 9.2 9 531.8 532  
 4 540 37.5 38 502.5 502  
Poon 2009c Early 1 472 0 1 472.0 471 <0.001 
 2 472 0.2 3 471.8 469  
201 
 
 3 472 1.5 9 470.5 463  
 4 472 42.2 31 429.8 441  
Poon 2009c Late 1 472 0.5 1 471.5 471 0.075 
 2 472 1.9 4 470.1 468  
 3 472 5.3 8 466.7 464  
 4 472 36.3 31 435.7 441  
202 
 
Appendix 7.1: Complete search criteria 
 
pregnancy, pregnant women, pregnant, gravidity AND preeclampsia, pre-eclampsia, 
PIH, gestational hypertension, hypertension AND statins, simvastatin, atorvastatin, 
pravastatin, pilavastatin, ifluvastatin, rosuvastatin, hydroxymethylglutaryl-Co-A 
reductase inhibitors OR fibre, dietary fibre, bran, isaphagula, methylcellulose, psyllium, 
fiber OR omega-3, fatty acids,  fish oil, cod liver oil, flax seed oil, krill oil, nicotinic acid, 

















Appendix 7.2: Clinical characteristics of the studies evaluating the effectiveness 








































































PIH defined as 
blood pressure of 
at least 
140/90mmHg on 2 
occasions 6 or 
more hours apart 
after 20 weeks of 






























gestation, with a 
75-g oral 
glucose-
tolerance test at 





was less than 
7.8 mmol /l after 
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fast and was 

















the 2nd trimester.  
Antenatal PE. PIH 
defined as blood 
pressure of at 
least 
140/90mmHg on 2 
occasions 4 or 
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mmol /l (198 mg 































































the 1st trimester 
PIH, oedema, PE, 
eclampsia. 
PE defined as 
clinical triad of 
oedema, 
hypertension and 




defined as a rise 
in systolic BP 
greater 
than30mmHg 




one or both during 
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week 17-20 to 
birth. 
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measured at 2 
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6 hours apart) with 
1+ proteinuria on 
a dipstick assay 














































defined as a 
systolic pressure 
of 140 mm Hg or 
more or a diastolic 
pressure of 90 
mm Hg or more 
on two occasions 
at least 4 hours 



















PE was defined as 
an elevation in 
blood pressure 






mg of protein or 
more in a 24-hour 
urine collection or 
a result of 2+ or 
greater on a 
dipstick test when 
a 24-hour 






















































Fish oil capsules 
giving 1.3g 
Eicospentanoiec 













PIH defined as 
one or more 
recorded 
measurements of 
a diastolic bp 
>90mmHg at rest. 































intake of fish oil 
or NSAIDs or 
other drugs with 

























































Fish oil given as 
9 capsules/day 
giving total dose 
1.62g 
Eicospentanoiec 













PIH, PE. Raised 
blood pressure 
was defined by a 
diastolic blood 
pressure of at 
least 90 mmHg on 
two consecutive 
occasions at least 
4 h apart 
Proteinuria was 




urine collected > 4 
h apart with 1 g 
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Fit for Delivery 
intervention was 
developed out of 
a preliminary 
study done by 












































































































































































serious bleed in 
current 
pregnancy, 







Fish oil (2.7g 





given 4 olive oil 
capsules/day or 
no supplements  
Intervention 
commenced in 
the 3rd trimester 
Systolic and 





considered to be 
present if arterial 
blood pressure 
was greater than 
140/90 mmHg 
after rest at two 
subsequent 
measurements 
with a 6 h interval. 
PE was 







































































































≥30 kg/m2) with 
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pregnancy, 
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more than one 
occasion. PIH was 
diagnosed if the 
blood pressure 










































































































































PE defined as PIH 
and proteinuria or 
clinically 
diagnosed PE 
diagnosis made in 
the clinical record, 
PIH was defined 
as either 1) one 
systolic blood 
pressure reading 

















acid, their fetus 
had a known 
major 
abnormality, 
they had a 
bleeding 
disorder for 















acid trial, or 








1st and 2nd 
trimester 
of ≥110 mm Hg or 
2) 2 consecutive 
systolic blood 
pressure readings 
of ≥140 mm Hg 
and/or diastolic 
blood pressure 
readings of ≥90 
mm Hg ≥4 h apart 
after 20 wk 
gestation.  
Proteinuria was 
defined as 1) a 
spot urine protein 
to creatinine ratio 
of ≥30 mg/mmol, 
2) one 24-h urine 
specimen with a 
total protein 
content of ≥0.3 g/L 
on a dipstick test, 
or 3) a total 
protein content of 
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